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PREFACE 
The work described in this thesis was carried out between February 2000 and June 2003. The 
work had two components, a field component which was carried out in Uganda, and a 
laboratory component most of which, was carried out in the laboratories of the Division of 
Clinical pharmacology, Department of Medicine at the University of Cape Town, South 
Africa. Some of the extractions were done in the Department of Chemistry at Makerere 
University in Uganda. 
The thesis has got six chapters preceded by an abstract> table of contents, lists of tables and 
figures, a dedication and acknowledgements. A list of important references is attached at the 
end of chapter 6 followed by appendices. Chapter one reviews important literature on malaria 
with the aim of justifying this study. This chapter also covers the scope and objectives of the 
study. The second chapter details the methods used in the study. The results of the study are 
presented in chapters three, four and five, each followed with a discussion and conclusion. 
Chapter six presents the general discussion. In this chapter we review the study objectives, 
summarise essential conclusions from the study, point out the relevance of study findings and 
its limitations. We also look at research prospects that may arise from the study findings. 
I have made a very effort to keep apace with contemporary literature and compare my results 
with existing information. This manuscript received inputs from my supervisors and a number 
of colleagues, and I have taken reasonable effort to rid it of any errors and redundanCies. 1 am 
however fully accountable for the final version. I hope readers will find it valuable. 
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ABSTRACT 
The study investigates the antimalarial potential of six Ugandan traditional medicinal plants 
Senecio disci/olius oliv, Senecio stuhlmannii, Indigojera emarginel/a steud. Ex A. Rich. 
Aspi/ia africana (pers) C.D. Adams, Cardiospermum halicacabum L. and Momordicajoetida 
Schumch. Et Thonn. Selection of the plants was based on ethnobotanical surveys of 
traditional treatment of malaria symptoms and reports from traditional healers practising in 
three different communities. 
Extracts from the plants were evaluated for in vitro activity against both chloroquine-sensitive 
(DI0) and chloroquine- and sulphonamide-resistant (Kl) strains of P. ja/ciparum. Extracts 
without in vitro antiplasmodial activity were tested for activity in a murine model of cerebral 
malaria. Bioassay-guided fractionation was carried out on active extracts. The antiplasmodial 
activity of one of the isolates was analysed geometrically to determine its interaction with 
chloroquine and artemisinin, respectively. S. disci/olius, S. stuhlmannii, l. emarginella and 
A. africana were shown to have antiplasmodial activity, the 50% inhibitory concentration 
(IC.5o) ranging 8.00 to 29.0 I-lglml against the two strains of P. jalciparum. There was 
positive correlation between the activity of the extracts against the chloroquine-sensitive and -
resistant strains (r=0.967, p=O.05). A sesquiterpene, referred to as AA2, with molecular 
weight 264.14 and molecular formula C1.5H2004 was isolated from A. africana. This isolate 
had antiplasmodial activity of IC.5o 1.8 (1.6-2.0) J.1g1ml. Another isolate, ACWl, with 
molecular weight 213 and IC.5o of 1.51(1.21-1.81) and 0.50 (0.26-0.86) I-lglml against DI0 and 
Kl, respectively, was isolated from another batch of A. africana. ACWI antagonised the 
antimalarial activity of artemisinin against both DIO and Kl, and of chloroquine against Kl, 
but was additive with chloroquine against DIO. ACWI in concentrations of 150, 350 and 
600nglml inhibited accumulation of 3H-dihydroartemisinin by erythrocytes infected with Kl, 
and enhanced its accumulation by D 1 O. The water extract of M foetida, a plant without in 
vitro antiplasmodial activity, delayed development of parasitaemia in mice and prolonged 
survival.to 20 days. 
V11 
This study provides evidence of in vitro antimalarial efficacy of S. discifolius, S. 
Stuhlmannii, 1. emargine//a and A ajricana, and of in vivo activity of M foetida. The 
results suggest that these Ugandan traditional medicines may have promising antimalarial 
potential for further development. 
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RESEARCH SUMMARY 
Parasite resistance to existing antimalarial drugs is on the rise, extending to new geographical 
areas and affecting species other than P. jalciparum, raising the need to 4evelop new malaria 
remedies. In Uganda, malaria is responsible for over 20% of the national disease burden. 
Many communities use traditional medicines in the treatment of malaria. The potential of 
Uganda's traditional medicinal plants as sources of malaria remedies has not been explored to 
date. This study investigates the antimalarial potential of six Ugandan traditional medicinal 
plants: Senecio disci/olius oliv, Senecio stuhlmannii, Indigojera emarginella steud. Ex A. 
Rich, Aspilia africana (Pers) C.D. Adams, Cardiospermum halicacabum L. and Momordica 
joetida Schumch. Et Thonn. The selection of these plants was based on ethnobotanical 
surveys on the traditional treatment of malaria related symptoms and reports from three 
traditional healers identified within the framework of the National Co.uncil for Traditional 
Healers Associations (NACOTHA) and practicing in three different communities. 
The extracts from the plants were evaluated for in vitro efficacy using the lactate 
dehydrogenase antiplasmodial assay against both the chloroquine.sensitive (DIO) and the 
chloroquine-and·sulphonamide resistant (KI) strain of P. jalciparum. Extracts that did not 
show in vitro antiplasmodial activity were tested for antimalarial activity using a murine 
model of cerebral malaria. The study plants were collected in two batches, during the wet and 
dry season to determine seasonal variations in yields and antimalarial activity. Bioassay-
guided fractionation was carried out on the active extracts. The antiplasmodial activity of one 
of the isolates from the study plants was determined in combination with chloroquine and 
artemisinin, and analysed geometrically to determine the nature of the interaction between the 
two. To determine the possible mechanism of action behind the interaction between 
artemisinin and the plant isolate, the accumulation of triated dihydroartemisinin CHDHA) by 
erythrocytes infected with the DIO strain and the KI strain of P. jalciparum was 
characterised. The effect of three extract doses on the uptake of3HDHA was determined. 
The plants: S. disci/olius, S. stuhlmannii, I emarginella and A. africana had antiplasmodial 
activity of 50% inhibitory concentration (ICso) ranging 8.00 to 29.0 f..lglml against the two 
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strains of P. falciparum. The ethyl acetate extract of A. africana was the most active from the 
two plant batches with ICso of 9.3 (7.7-10.9) Jlglml against the DI0 strain and 11.5 (8.7-14.3) 
Jlglml against Kl strain of P. falciparum during the wet season and ·8.00 (5.30-10.70) Jlglml 
against the D 1 0 strain during the dry season. There was a positive correlation between the 
activity of the extracts against the chloroquine-sensitive and the resistant strain (pearsons' 
coefficient r =0.967, p=0.05), with no significant difference between the activity of the 
extracts on both strains. The plant batch collected in the wet season had better yields than one 
collected during the dry season. Extracts from S. Stuhlmannii, and 1. emarginella collected 
during the dry season had better antiplasmodial activity than those from the plant batch 
collected in the wet season. A sesquieterpene, referred to, as AAZ in our laboratory with 
molecular weight of 264.14 and a molecular formula of C1sH2004 was isolated from A. 
africana. This isolate had antiplasmodial activity of 1.8 (1.6-2.0) Jlglml. Another isolate 
from A. Africana, ACWI with molecular weight of 213, and antiplasmodial activity of ICso 
1.51(1.21-1.81) and 0.50 (0.26-0.86) Jlglml against the DI0 strain and Kl respectively was 
isolated from another batch of A. africa. The isolate ACWI antagonised the antimalarial 
activity of artemisinin against both the DIO and KI strains of P. falciparum. The same isolate 
antagonised the antimalarial activity of chloroquine against the KI strain but had an additive 
effect with chloroquine against the D I 0 strain of P. falciparum. The accumulation of 
dihydroartemisinin 3HDHA by erythrocytes infected by both the D I 0 and K 1 strains of P. 
falciparum was characterised to be temperature dependent and saturable although the Kl 
strain accumulated 3HDHA more efficiently than the DIO strain. The isolate, ACWI at the . 
study doses: 150, 350 and 600nglml inhibited the accumulation of 3HDHA by erythrocytes 
infected with the chloroquine-resistant Kl isolate of P. falciparum. On the other hand the 
same test doses caused enhanced accumulation of 3HDHA by erythrocytes infected with the 
chloroquine-sensitive D I 0 strain of P.falciparum. 
The water extract of M. foetida a plant whose extracts did not show any in vitro 
antiplasmodial activity was well tolerated in oral doses as high as 1000mglkglday by C57BL 
mice infected with P. berghei (Anka). The above dose delayed the development of 
parasitaemia in mice for 6 days and prolonged the survival of mice infected. intraperitoneally 
with Ixl07-infected erythrocytes to 20 days. The mean survival infected mice increased with 
dose of the extract. The water extract of C. halicacabum was not tolerated, with all the study 
animals dying with in the first four days of the experiment. 
x 
This study provides evidence of antimalarial efficacy for the plants: S. discifo/ius, S. 
Stuhlmannii, I. emarginella and A Africana based on in vitro findings and M foetida basing 
on animal studies. There are seasonal variations in yields of active principles and 
antiplasmodial activity. There is no cross-resistance between the traditional medicines studied 
and chloroquine suggesting that remedies based on traditional medicines can be used to treat 
both chloroquine-sensitive and chloroquine-resistant malaria. Ugandan traditional medicines 
can also be sources of lead compounds for the development of antimalarial drugs. Some 
traditional medicines antagonise the antimalarial activity of antimalarial drugs a situation, 
which could contribute to treatment failure in many communities. It is our conclusion that 
Ugandan traditional medicines have a high antimalarial potential. 
xi 
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Introduction, literature review and scope of the study 
1.1 Introduction 
Malaria, a disease perhaps as old as mankind, is caused by obligate intracellular protozoa of 
the genus Plasmodium. Records on deadly fevers that could have been due to malaria are 
found in the Indian Vedic writings of 1600 B.C (Desowitz, 1991). The origin of this disease is 
not certain but human movements are responsible for its spread. Today, people present with 
malaria in all parts of the world. This disease has a short natural history and may result in 
death ifuntreated. 
In this chapter we give an overview of the current global malaria disease burden, 
transmission, pathogenesis and control measures. The Uganda experience with malaria is 
discussed, together with potential solutions to this problem. There is a section that discusses 
the status, organisation and practice of traditional medicine in Uganda. In the last part, a study 
that investigates the antimalarial potential of Ugandan traditional medicines is introduced. 
1.2 Malaria disease burden, transmission, pathogenesis and control 
1.2.1 The malaria disease burden 
More than two-thirds of the world's population are living in malaria endemic areas. It is 
estimated that 200 million people show signs and symptoms of malaria every year of which 
one to two million people succumb annually to the disease (Wernsdorfer, 1998). Most of the 
malaria victims live in the developing part of the world, where the average yearly per capita 
income is between 200-600 United States dollars (USS) and government expenditure on 
health is extremely low. The exact economic impact of malaria in these countries is difficult 
to assess due to a lack of relevant data; however, it is estimated that the average cost of a 
malaria attack to a family in sub-Saharan Africa is close to 12 USS (Ettling and Shepard, 
1991 ). With the emergence of multi-drug resistant strains of Plasmodium and, despite 
widespread national efforts to combat malaria, the incidence of the disease is on the rise in 
many countries (Chattopadhyay and Sengupta, 2000; Accorsi et al.. 2001, and Ndiaye et al., 
200 1) and the world is facing an increasing disease burden (WHO, 1998). This is attributed to 
population growth, increased global movements, changing agricultural practices, weakening 
of public health systems, long-tenn environmental changes and global warming. These factors 
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The Plasmodium species spends part of its life-cycle in both a vertebrate and invertebrate 
host. Man is the vertebrate host of the human species of Plasmodium. In the vertebrate host it 
is found both in the liver cells and outside liver cells, either inside or outside the erythrocytes. 
The insect vector for human malaria is the mosquito of the genus Anopheles, Order: Diptera, 
Family: Culicidae and Subfamily: Anophelinae. The species within the Anopheles gambiae 
complex that are responsible for the transmission of malaria in Africa are: A. arabiensis, A. 
bwambae, A. gambiae s.s, A. melas, A. merus and A.quadriannulatus. The variety. of malaria 
vector species has ensured the existence of at least one malaria transmission vector in most 
tropical habitats (Rogers et aI., 2002). 
1.2.3 Life-cycle of the malaria parasite 
Human infection is initiated when the mosquito, through its bite, inoculates sporozoites into 
the blood stream. The sporozoites are carried to the liver parenchyma cells, which they invade 
and there develop into merozoites through a process of fission called schizogony. The 
infected liver cells burst to release merozoites about two weeks after the mosquito bite. The 
merozoites then invade red blood cells, where they develop into ring forms. These mature 
within hours to trophozoites and later to erythrocytic schizonts. The schizont-infected cells 
burst to release merozoites, which then invade other erythrocytes forming an erythrocytic 
cycle. Sexual stages form in some erythrocytes, which are then taken up into the mosquito 
when taking its blood meal. The female and male gametocytes meet and develop into an 
oocyst in the gut wall of a mosquito. The oocyst develops into sporozoites within 2 weeks and 
move to the mosquito salivary glands where they mature ready for the next part of the parasite 
life cycle. 
1.2.4 Immunological response to malaria parasites 
The malaria parasites go through several stages in the animal host, each stage exposing 
specific antigen characteristics. The human immune system responds differently to the pre-
erythrocytic stage antigens and erythrocytic stage antigens. Both Thl and Th2 responses play 
a role in the active immunological response to malaria. The response to the pre-erythrocytic 
stages is largely a Th 1 response. The macrophage presents the parasitic antigen to the T-
lymphocytes, which then release IFN-y and IL-2; the latter are responsible for the 
proliferation of CD8 (+) T cells into cytotoxic cells and the release of nitric oxide by 
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macrophages, which kill the parasitised erythrocytes. Interferon-y serves also to amplify and 
enhance the production of TNF-a. (by macro phages), IL-IO and IL-12 (by CD4+ cells), 
besides the malaria toxin directly causes release of TNF-a. by macrophages (Kwiatkowski et 
al., 1989). Although TNF-a. causes proliferation of CD8+ cells, it has also been implicated as 
the causative agent of several pathological changes in malaria. Severe fonns of malaria are 
associated with raised levels of TNF-a. and IL-IO (Shaffer et al., 1991) and down-regulation 
ofIL-12 activity (Peyron et al., 1994). 
Development of passive immunity to malaria in humans takes a number of years and it is not 
absolutely protective. It is possible that this is due to factors such as antigenic variation, 
antigenic polymorphism, and poor immunological responses to critical antigens. The 
immunological response to malaria is not fully understood but varies with infecting species, 
previous exposure to the host and severity of disease. These factors combined have made it 
difficult to develop antimalarial agents with immunomodulatory activity and put prospects of 
a malaria vaccine distant. 
1.2.5 Clinical aspects of the malaria infection 
Plasmodium jalciparum accounts for most of the human malaria infections and is responsible 
for almost all severe fonns of malaria. The species P. malariae. P. ovale and P. vivax are 
other important human pathogens. There have been some reports of accidental transmission of 
simian malaria to man by P. cynomolgi and P. knowlest (Most, 1973, Cross et aI., 1973), but 
these are far less epidemiologically important. 
The clinical features of human malaria include fever, anaemia, cerebral symptomatology and 
> 
non-specific symptoms including headache, malaise, diarrhoea and dyspepsia. Cerebral 
malaria is the most life-threatening fonn of malaria, presenting with high parasitaemia, 
convulsions and respiratory distress. Cerebral malaria is commonly caused by P. jalciparum 
but rare cases caused by P. vivax (Arora et al., 1988, Sachdev and Mohan, 1985, Mishra and 
Singh, 1989) have been reported. Other important complications of falciparum malaria 
include renal failure, spontaneous bleeding, haemoglobinuria and algid malaria (Chishti et al., 
2000). While the malaria parasite can directly cause organ damage, the immunological 
response to the parasite is responsible for major symptoms such as fever (Richards et al., 
4 
Introduction, literature review and scope of the study 
1997). Anaemia. occurs in symptomatic and asymptomatic malaria and is mainly due to 
haemolysis unmatched by compensatory haematopoiesis (Burchard et al., 1995, Burgmann et 
al., 1996). Bone marrow suppression contributing to anaemia has been suggested by 
Kurtzhals and colleagues (Kurtzhals et al., 1997, Kurtzhals et al., 1999). The convulsions in 
cerebral malaria are due to hypoxia and possibly hypoglycaemia, while respiratory distress is 
due to lactic acid accumulation (English et al., 1996) as a result of reduced delivery of oxygen 
to tissues (English et al., 1997). Prostaglandins and cyclic AMP have been reported to be 
involved in the development of diarrhoea in malaria (Hertelendey et al., 1979) and several 
cytokines are known to cause tissue injury. 
1.2.6. Prognosis of malaria 
The proportion of malaria infections that results in death is still high in many parts of the 
world (Webster, 2001). The prognosis depends on pathogen and host factors. Infections due to 
P. falciparum may present with high parasitaemia, have a high incidence of multi-drug 
resistance, and have been associated with poor prognosis (Mehta et al., 1998). Other factors 
affecting prognosis include nutritional status, age and physiological state of the patient (Hess 
et aI., 1997, Olumese et aI., 1997, Murphy et aI., 2001 and Singh et aI., 1999). Despite 
advances in knowledge of the management of malaria in the previous decade, the prognosis.of 
malaria remains poor, especially among young children and pregnant mothers. The treatment-
seeking ·behaviour and poor access to effective and good quality drugs may contribute to the 
poor prognosis. 
1.2.7 Control of malaria 
The prospects of eradicating malaria by the mid-1950s raised optimism in the global control 
of malaria. The World Health Organisation (WHO) launched the first global malaria 
eradication campaign in 1955. This campaign has not been successful in tropical countries 
due to climatic, social and economic reasons (de Zulueta, 1998). The key elements in the 
malaria eradication campaign include modification of the vector habitat, eradication of the 
mosquito, prevention of mosquito bites, chemoprophylaxis and. treatment of malaria-infected 
patients. 
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Modification of the mosquito habitat includes ensuring that there is no stagnant water and 
bushes near human residences, which seIVe as breeding grounds for the mosquito. While these 
were once appropriate methods of controlling malaria, current pressures to conseIVe the 
environment have reduced their application. Emphasis is now put on improving the quality of 
housing which has been found to reduce infection with malaria by close to 44% in Malawi 
(Wolff et al., 2001). The adaptation of the mosquito vector to new environments that has been 
obseIVed in some areas is a major threat to this method (el-Amine, 1995). 
The parasite development of resistance to the major insecticides is a major setback to efforts 
aimed at eradicating the mosquito (Curtis, 2001). Insecticides affect the environment in many 
ways even when used in low concentrations (McLean et ai., 1975) and the price of many 
insecticides is prohibitively high. Even the cost of dichlorodiphenyltrichloroethane (DDT) is 
on the rise as a result of decreased production (Walker, 2000). 
Mosquito nets and insect repellents are effective in the prevention of mosquito bites (Govere 
et ai., 2000). Insecticide impregnated nets are now considered to be a more effective way of 
preventing mosquito bites and field studies have shown that they reduce mortality due to 
malaria (Aikins et ai., 1998). The high cost and poor availability of the nets results in poor 
adherence, increasing the risk of selecting mosquitoes resistant to the commonly used 
insecticides (Vulule et ai., 1999, Santos, 1999). 
Chemoprophylaxis is one of the most important ways of preventing malaria infection amongst 
people visiting malaria endemic areas. The commonly used drugs are doxycycline, 
mefloquine and a combination of chloroquine and proguanil. However these drugs are not 
free of side effects and have interactions with other drugs and certain diseases. Development 
of resistance to the commonly' used chemotherapeutic agents limits the effectiveness of 
malaria chemoprophylaxis. 
Early diagnosis and treatment of malaria is an important component of malaria control 
programmes. The first choice treatment of malaria varies from one region to the other, 
depending on the resistance pattern in the area and the resources available. It is, however, 
generally accepted that the treatment of choice for cerebral malaria is intravenous quinine, 
with doxycycline added for patients from non-endemic areas. The development of artemisinin 
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derivatives is a great contribution to malaria chemotherapy. They are effective against multi-
drug resistant strains of P. Jalciparum, and have a quick onset of action with a favourable 
safety profile. 
A malaria vaccine might be the most cost-effective way of preventing malaria (Graves, 1998, 
Goodman and Mills, 1999). By 1998, close to 40 phase 1 and 2 vaccine trials had been carried 
out on synthetic peptides or recombinant proteins based on the malaria antigen (Engers and 
Godal, 1998). However, only a few field trials have been conducted especially with the 
synthetic peptide SPf66. A meta-analysis of nine field trials of this candidate vaccine shows 
evidence of some protection against malaria in South America, but no efficacy in Africa 
(Graves and Gelbrand, 2003). Developing a vaccine against malaria presents formidable 
challenges. It requires substantial investment of resources and capacity to handle trials; above 
all, preliminary studies lack validated models that can reliably predict the protection a vaccine 
can give to humans (Richie and Saul, 2002). Nevertheless, we expect to see more candidate 
vaccines undergoing field trials in the near future. 
1.2.8. Malaria in Uganda 
Uganda is located between 4° N, 1° S, 30° W and 34° E in a highly malaria endemic area. 
Malaria accounts for 25-40% of all outpatient visits at health facilities and 20% of all hospital 
admissions (Uganda Ministry of Health, 2003). In Mulago hospital, Kampala, Uganda's 
largest university teaching hospital, about 500 patients are admitted monthly due to malaria 
and its complications (Medical records, 2002), making it the single most important reason for 
hospital admissions. The direct cost oftreating a malaria episode in Uganda is estimated to be 
4.1 US$ in the urban areas and slightly less than this in the rural areas. It is estimated that the 
country loses close to US$3s0 million a year due to malaria (Associated Press, 2902). 
In Uganda, malaria is commonly caused by P. Jalciparum, whose transmission is on the rise 
due to increasing environmental modifications, many of which have created breeding sites for 
the anopheles mosquito. Malaria transmission is generally highest during the wet season, 
unfortunately the busiest time in this predominantly agricultural country. The problem of 
refugees and internally displaced people as a result of conflicts in the Great Lakes Region 
poses serious challenges to the malaria control programmes. The elements of the malaria 
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control programme include curative treatment and vector control using insecticides and 
mosquito nets. The first-line treatment of malaria is chloroquine in combination with 
sulfadoxine / pyrimethamine. While the potential of traditional medicines is acknowledged, 
nothing systematic has been done to explore this. 
1.3 Malaria chemotherapy and drug discovery 
1.3.1 Principles of malaria drug therapy 
The current principles of malaria chemotherapy are based on Paul Ehrlich's concepts (Bruce-
Chwat, 1988). He postulated that pathogenic organisms have chemoreceptors that differ from 
one another, some of which have no analogues on human cells. He further postulated that an 
alien chemical compound cannot be completely harmless to the human cells and tissues, but 
the more acceptable it is, the higher the dose that can be administered. Compounds acting 
against parasites are selected on the basis of their selective toxicity in relation to mammalian 
cells. 
1.3.2 History of malaria chemotherapy 
Malaria' chemotherapy was first recognised in the seventeenth century when cinchona bark 
was used in the treatment of malaria fever in Latin America (Bruce-Chwat, 1988, Dobson, 
1998). In 1820, quinine was isolated from the cinchona bark but it was only identified as a 
quinoline in 1908 (Gramiccia, 1998). Quinine served as the standard treatment for malaria to 
the end of World War I. The sanctions imposed on Germany after World War I led to 
increased research aimed at developing semi-synthetic analogues of quinine. A number of 
successful antimalarials have been developed as a result of these efforts. 
1.3.3 Classification of antimalarial drugs 
The drugs used in the treatment of malaria are classified either on the basis of the stage of the 
parasite cycle affected (biological classification) or on the chemical class to which they 
belong. 
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Biological classification 
Antimalarial drugs are classified into tissue schizontocides, drugs acting on the hypnozoites, 
and blood schizonticides. 
Tissue schizontocides: These affect pre-erythrocytic stages of the parasite in hepatocytes. 
Examples include proguanil and pyrimethamine. They are used in causal prophylaxis. 
Drugs acting on the hypnozoites: These affect dormant liver stages. An example of such a 
drug is primaquine. These drugs are used to prevent relapse of P. ovale and P. vivax malaria. 
Blood schizonticides: These act on the erythrocytic stages ofthe parasite and are generally the 
most widely used antimalarial agents. Examples include quinine, chloroquine, amodiaquine, 
mefloquine, pyronaridine, artemisinin derivatives and atovaquone. 
Chemical classification 
Antimalarials drugs are classified into the quinolines and related antimalarial compounds, 
artemisinin derivatives, antifolates, and other antimalarial drugs. Each of these classes has a 
characteristic chemical skeleton (Ridley RG., 2002). 
Quinoline and related antimalarials: These include qUlmne, chloroquine, amodiaquine, 
mefioquine, halofantrine and lumefantrine. Except for quinine, which is a plant derived 
natural product, the others are fully synthetic compounds based on the quinine structure. The 
site of action ofthese drugs is believed to be the food vacuole ofthe parasite. 
Artemisinin derivatives: These are the semi-synthetic derivatives of artemisinin, an isolate 
from the Chinese herb Artemisia annua L. They include artemether, arteether, artesunate and 
their main active metabolite dihydroartemisinin. The exact site of action of the artemisinin 
derivatives has not been conclusively elucidated but most studies point to the food vacuole as 
the most probable site of action (Hong et al., 1994, Pandey et al., 1999). The antimalarial 
activity of these compounds is closely linked . to the unstable peroxide bridge, which is 
confined in their structure. 
Anti/olates: The most widely used antifolates are pyrimethamine and sulphadoxine. They 
interfere with the enzymes dihydrofolate reductase and dihydroopteroate synthase, important 
enzymes in the folate synthesis pathway. The pathway is necessary for nucleic acid synthesis. 
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Other antimalarial drugs: These include atovaquone, proguanil and antibiotics like 
tetracyclines and clindamycin. 
Of all the antimalarials in use, chloroquine has in the past been the most universally 
successful. Although at the time of its discovery it was considered to be toxic, it is now 
generally known to be the safest antimalarial in children and pregnant women (phillips-
Howard and Wood, 1996). The potential teratogenicity that has been demonstrated in vitro 
(Ambroso and Harris, 1994, Landauer, 1978) has never been observed clinically. Its 
favourable pharmacokinetic profile (Krishna and White, 1996) and low cost are responsible 
for its widespread use. Intravenous administration can however lead to fatal hypotension and 
overdose causes hypokalemia, hypotension, nuerotoxicity with convulsions, and ventricular 
tachyarrhythmias (Jordan et al., 1999). Even now that P. Jalciparum strains have become 
resistant to chloroquine, its use is still promoted in many countries (Rab, 2001)' Other 
commonly used antimalarials have important side effects. Amodiaquine is associated with 
agranulocytosis and hepatic toxicity when used for prophylaxis. Quinine is associated with 
blackwater fever and cardiac toxicity, and mefloquine may cause convulsions, depression, 
psychotic episodes, and toxic encephalopathy (Bem et al., 1992)' Methaemoglobinaemia and 
haemolysis commonly in people with g1ucose-6-phosphate dehydrogenase deficiency, have 
limited the use of primaquine in malaria prophylaxis. 
1.3.4 Parasite resistance to antimalarial drugs 
One of the greatest challenges to malaria chemotherapy is the development of drug-resistant 
strains of Plasmodium. As early as 1968 cases of chloroquine-resistant P. jalciparum had 
been reported (Modell, 1968). Since then, several strains of Plasmodium resistant to various 
drugs have been reported ~d recently multi-drug resistant malaria has been reported in;. 
several parts of the world (Mutanda, 1999). The emergence of drug-resistant P. jalciparum 
has increased the incidence of severe malaria and its mortality (Trape et al., 1998; Trape, 
2001). Many countries in Africa have changed their first-line drug from chloroquine to 
pyrimethamine-sulfadoxine, and some countries are using both drugs. This has raised the cost 
of treating malaria and increased the incidence of pyrimethamine-sulfadoxine resistant strains 
of P. Jalciparum (Ronn et al., 1996). Drug resistance has mostly been reported in P. 
jalciparum species~ however, there are also reports of multi-drug resistance in P. vivax 
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(Kshirsagar et aI., 2000; Alecrim et al., 1999), indicating that drug resistance is spreading to 
plasmodium species other than P. Ja/ciparum. 
The problem of parasite resistance is being approached on three fronts: (i) reversing 
chloroloquine resistance; (ii) combination therapy; and (iii) discovery of new antimalarial 
compounds (White et al., 1999). 
1.3.5 Reversal of chloroquine resistance 
Since the advent of chloroquine resistance, much research has been done in the field of 
resistance reversal. The mechanism of resistance reversal is not clear, but many agents that 
reverse chloroquine resistance potentiate chloroquine accumulation in the parasite vacuole 
(Van Schalkwyk et aI., 2001). Compounds reported to reverse chloroquine resistance in vitro 
include calcium channel blockers, tricyclic antidepressants, antihistamines and phenothiazine 
derivatives (Bhattachatjee et al., 2001, Ye and Van Dyke, 1994). Although a study of seven 
compounds: verapamil, chlorpromazine, prochlorperazine, cyproheptadine, ketotifen, a 
tiapamil analog (Ro 11-2933) and a chlorpromazine, have shown a correlation between in 
vitro and in vivo chloroquine resistance reversal activity (Kyle et aI., 1993), there is need for 
this to be supported by clinical trials. Attempts to identify compounds from traditional 
medicinal plants that might reverse chloroquine resistance, have lead to isolation of 
malagashanine, a parent compound for a number of indole alkaloids from Malagasy 
strychnos, which reverses chloroquine resistance in vitro and in vivo (Rafatro et al., 2000). 
1.3.6. Use of combination therapy 
A number of countries have turned to combination therapy for first-line treatment of malaria. 
Drug combinations presently being used around the world include sulfadoxine~pyrimethamine 
(SP) with the 4-aminoquinolines, artemisinin derivatives and SP, and artemisinin derivatives 
and mefloquine. Drug combinations have a double effect, clearing the parasites completely 
and thus reducing transmission, and delaying emergence of resistance. There is a need for 
clinical trials and field trials to demonstrate these advantages and to show that these drug 
combinations are safe. 
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1.3.7. Antimalarial drug discovery 
Drug discovery is part of a long process of drug development that traditionally includes drug 
design, pre-clinical studies, clinical studies, field studies and post-marketing surveillance. A 
successful drug discovery programme would result in identification of a lead compound. The 
lead compound might be a drug already in clinical use or a molecule that has never been used 
as a drug before. New drugs could be generated by computational methods based on a specific 
validated drug target, or isolated from an organism. Knowledge of the molecular targets in 
the parasite of existing antimalarial drugs is important if it is to be ensured that new drugs are 
developed to avoid cross-resistance. 
While the orthodox and systematic way of drug development is well known, the development 
of traditional medicines for use as herbal remedies is not well established. The WHO has 
issued guidelines for the development of herbal medicines (WHO, 2000). The important 
component is the recognition of traditional experience as evidence for efficacy. The other 
important component is the recognition of phytomedicines as a combination of more that one 
principle and could be used as such. 
1.3.8. Potential antimalarial drug targets 
A potential target for a chemotherapeutic agent is normally an essential component of the 
parasite structure or metabolic pathway that is rate limiting and has no alternative pathway. 
Heme metabolism in the food vacuole of Plasmodium is an example of an antimalarial drug 
target. The detoxification of haem and antioxidant defence mechanisms that occur in the 
vacuole are critical to parasite survival. During haemoglobin digestion, an aspartic 
haemoglobinase is responsible for the breakdown of haemoglobin (Francis et al., 1994). The 
"presence of a peptidomimetic inhibitor that selectively blocks aspartic haemoglobinase 
provides a good starting point for the development of new antimalarial drugs at this target. 
The cytoplasm and cell nucleus are the site for nucleic acid metabolism, phospholipid 
metabolism, glycolysis, and tubulin assembly. These can act as potential targets for new 
antimalarial drugs. Recently, some attention has been paid to the fatty acid biosynthetic 
pathway as a potential target; this is as a result of the discovery of sphingomyelin synthase in 
the Golgi apparatus of human P. Ja/ciparum. This enzyme is also found in the tubovesicular 
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membranes in the cytoplasm of infected erythrocytes and is considered important in the 
development of the tubular network in the erythrocytes that transports nutrie~ts to the 
parasite. It has already been reported that inhibitors of this enzyme block parasite proliferation 
in culture (Lauer et aI., 1995). 
Another potential target is the P. jalciparum plasma membrane. The integrity of the plasma 
membrane is critical for the intracellular survival of P. ja/ciparum. Pathways for the 
trafficking of nutrients start at this point and it also mediates intracellular signalling. These 
pathways are critical for the intracellular survival of Plasmodium, which makes it a good 
target for novo antimalarial agents (Olliaro et ai., 1999). Logically in the search for novo 
antimalarial agents, a combination of inhibitors acting on pathways that converge to produce a 
final product, could be more effective than a single inhibitor, and reduces the rate of evolution 
of drug resistance. 
1.3.9 Plants as sources of antimalarial drugs 
Plants pioneered malaria chemotherapy when cinchona bark was used successfully to treat 
Cardinal Juan di Luigi in 1632. Many authors recount the story of the cinchona bark powder, 
which had historically been used to treat fever and later found to contain quinine (Sharma and 
Sharma, 1998, Dobson, 1998, Bruce-Chatt, 1988). Quinine, an alkaloid, was first extracted by 
French chemist Pelletier in 1834, and has remained an effective drug even with the prevalence 
of multi~drug resistant parasites. Since the elucidation of the quinine structure, it has been 
used as a template for some of the most widely used drugs in malaria treatment and 
prophylaxis. Another landmark in malaria chemotherapy is the isolation of artemisinin from 
Artemesia annua L, a Chinese herb, whose use in Chinese traditional medicine is traced as far 
back as 186 BC. Artemisinin and its derivatives (artemether, artesunate and arteether) are 
now being used to treat infections caused by chloroquine-resistant P. jalciparum and cerebral 
malaria. There are several compounds that have been isolated from plants that possess 
significant anti plasmodial activity that can be followed up. Triterpenoids and f3-carboline 
alkaloid glycosides derived from the stems of Brucea javanica have shown inhibition of 
chloroquine-resistant P. ja/ciparum strain in vitro (Kitagawa et aI., 1994). A 
naphthylisoquinoline alkaloid, named ancistroheynine A, from the Indian Ii ana 
Ancistrocladus heyneanus has also been shown to display pronounced in vitro activity against 
13 
Introduction, literature review and scope of the study 
P jalciparum (Bringmann et al., 1996). Another indole alkaloid cadambine, a major 
constituent of A. chinensis, was shown to exhibit moderate growth-inhibitory activity against 
the malarial parasite P. Jalciparum (Kitagawa et al., 1996). Naphthylisoquinoline alkaloid-
containing extracts from the plants A. barteri, A. heyneanus, A. robertsoniorum, and A. 
tectorius, used to treat fevers in several tropical countries, have shown high antiplasmodial 
activity against asexual erythrocytic forms of P. Ja/Ciparum (NF 54, clone AIA9) and P. 
berghei (Anka) in-vitro (Francois et al., 1997). Plant derived naphthaquinones have been used 
as starting molecules for the synthesis of atovaquine, an antimalarial that inhibits 
mitochondrial electron transport (Ridley R. G, 2002). In Africa, Cryptolepis sanguinolent a a 
plant widely used in West Africa for the treatment of many ailments has both in vitro and in 
vivo antiplasmodial activity (paulo et aI., 2000; Cimanga et al., 1997). The list of plants 
whose extracts have antimalarial potential is long, yet there are many plant species that have 
not been investigated at all. Plants have a high potential to produce antimalarial drugs and 
they are arguably the single most important source of antimalarial lead compounds. 
1.3.10. Evaluation of antimalarial agents 
Potential antimalarial agents are evaluated for both efficacy and safety during the process of 
drug discovery. In both cases, in vitro and in vivo studies are carried out. Evaluation for 
efficacy either in vitro or in vivo requires techniques for detection and quantification of 
Plasmodium in cultures and body fluids. Evaluation of safety in vitro requires detection and 
quantification of cellular chemical injury or death (cytotoxicty). In experimental animals 
safety is studied by observation and laboratory monitoring of body function parameters. 
Detection and quantification of plasmodium 
The techniques for detection and quantification of malaria parasites have improved; 
tremendously over the past three decades. Evaluation of in vitro activity of potential 
antimalarial agents requires an assay that is fast, reliable and easy to interpret. 
Light microscopy: Light microscopy is the oldest method of detecting Plasmodium. The first 
case of malaria was linked to haemoparasites by light microscopy of unstained blood smears. 
The development of giemsa-stained light microscopy made detection of plasmodium easier 
and is widely used in the diagnosis of malaria. While giemsa-stained microscopy is very 
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sensitive and used as a standard in the validation of most modem tests, it is time-consuming 
and a high level of sensitivity is attained only with experienced hands. 
Fluorometry: Methods based on fluorometry have been developed; they involve use of DNA 
staining dyes such as ethidium bromide, acridine orange and benzothiocarboxypurine. Their 
sensitivity parallels that of isotopic studies (Tamura et al., 1986) and geimsa-stained 
microscopy. Based on DNA staining, the detection of DNA fragments from dead parasites 
limits the specificity of the tests and utilises carcinogenic dyes. 
Antigen capture: A number of techniques based on antigen capture have been developed. The 
key antigens include histidine-rich protein 2 surface antigen and the parasite lactate 
dehydrogenase enzyme. These tests are very sensitive with the latter comparable to 
Polymerase Chain reaction (PCR) (Druilhe, et al., 2001). They however use monoclonal 
antibodies that render them expensive. 
Isotopic assays: Isotopic assays are one of the most sensitive methods used for the detection 
of plasmodium. They are based on the utilisation of hypoxanthine and adenosine in nucleic 
acid synthesis by P. Ja/ciparum. One of these is normally used as radiolabelled precursor. 
These two precursors produce virtually identical results (Ye, et al., 1987). The isotopic assays 
are sensitive, reproducible and fast, but they require specific precautions for the handling of 
radioactive material. 
Parasite lactate dehydrogenase assay: This is based on the principle that the amount of 
(PLDH) in a sample correlates with the degree of parasitemia. (Makler and Hinrichs, 1993). 
The fact that pLDH uti1izes 3-acetyl pyridine NAD (APAD) to APADH, that has the ability to 
reduce a yellow nitroblue tetrazolium (NBT) salt to a blue formazan product whose 
absorbance can be measured by microplate reader, makes it possible to measure pLDH. When 
used to evaluate drug sensitivity, this assay is reproducible, easy to interpret, rapid and 
inexpensive to perform and does not involve handling of radioactive material (Makler et al., 
1993). 
In vitro cytotoxicity 
Most of the assays used in cytotoxicity studies are based on determination of cell viability. 
One of the most used assays is the 3-(4,5-dimethylthiazol-2-yl)-2,5-
IS 
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diphenyltetrazoliumbromide (MTT), an assay that detects metabolic viability of the cells in an 
in vitro system (Mosman, 1983). Assays based on lactate dehydrogenase quantification have 
been used to assess cellular injury to mammalian cells (Fischer et al., 2003). These and other 
cytotoxicity assays require the maintenance of cell lines in culture, and are carried out in 
separate experiments from those used to determine antiplasmodial activity, increasing the cost 
and time of investigation. The quantification of haemoglobin in erythrocyte culture media is 
the basis of the erythrocyte haemolytic assay that can be used to investigate cytotoxicity of 
xenobiotics (Winski et al., 1997). Results from this assay could be extrapolated to other cells, 
since all ceJls have lipids in their cell membrane structures. This assay has the advantage that 
it can be carried out using the same reagents and conditions as the antiplasmodial assay. 
Further more, erythrocyte morphological changes on exposure to a potential chemotherapeutic 
agent can provide qualitative information on possible cellular injury (Bessis, 1973). While 
electron microscopy provides detailed information on morphological changes, simple giemsa-
staining can provide important basic information. 
In vivo evaluation 
The screening of compounds for in vivo antimalarial activity requires an animal disease model 
akin to human malaria. The animal host should absorb, metaboIise and excrete the test 
antimalarial agent in the same way as humans. Animal studies have the advantage of 
providing safety information in addition to antimalarial properties. Safety information is 
obtained by observing animal survival, behavioural changes and, changes in biochemical and 
haematological indices. Animals used in experimental malaria models include primates, birds 
and rodents. 
Primates: Primates are phylogenically close to humans and share most of the human 
physiological processes. They are receptive to adapted human plasmodium strains that are 
passaged several times in splenectomised animals. Despite these advantages their use has 
reduced tremendously over the past thirty years due to limited availability. They are difficult 
to handle, take a long time to breed, and most species have been listed as endangered. 
Birds: The big phylogenetic gap between birds and humans, together with interspecies 
variations in response to the same plasmodium species, limits the use of birds as models of 
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experimental malaria. The plasmodium species affecting birds are very different from the 
mammalian species. 
Rodents: Rodents are the most common hosts of experimental malaria because of their close 
proximity to humans and ease in laboratory handling. Rodent malaria species include P. 
berghei, P. chabaudi, P. yoelii and P. vinckei. Genetic modifications have been carried out on 
rodent strains to suite a wide range of investigations. Examples of transgenic mice used to 
understand malaria include the interferon-y (IFN-y) gene knock-out mice that have been used 
to study the role of interferon-y in the progress of cerebral malaria (Senaldi et al., 1999), and 
the T - and B-cell depleted mice (SCID) that have been used as a host of human erythrocytes 
in a rodent model of P. falciparum malaria (Moreno et al., 2001). 
1.4 Traditional medicines 
1.4.1 Definition 
Traditional medicinal practices are used in the prevention, diagnosis and treatment of physical 
and mental illnesses based on the theory, beliefs and experiences indigenous to the culture of 
a community. The terms 'traditional medicine', 'indigenous medicine' and 'folk medicine' 
can be used interchangeably. Communities around the world have traditional medicine 
systems that are considered alternative to western medicine. Some of the popular forms of 
alternative medicines are Ayurveda, Homoeopathy, Dnani, Siddha, Naturopathy, Yoga 
therapy; Acupuncture, Acupressure, Magnetotherapy, Shiatsu, Herbalism, Meditation, 
Aromatherapy, Bach Flower Remedies, Gem therapy, Chromotherapy, Hydropathy, Diet 
Therapy and Reiki. 
1.4.2 Traditional medicines in health care 
The use of traditional medicines around the world is on the rise (Chou, 200 I). In sub-Saharan 
Africa, more than 80 percent of the population relies on traditional medicines as their primary 
source of health care (WHO, 2002). The cost and poor access to allopathic medicines 
contributes to the popularity of traditional medicines. In many communities culture links 
people to traditional medicines making people perceive them as readily accessible, 
understandable and safe, with an acceptable mode of payment. 
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Plants by far are the most important sources of traditional medicines. It is estimated that at 
least 80% of countries where malaria is endemic have well-established antimalarial herbs 
(Sesay, 2000). Traditional medicines are administered both as self-medicaments and by 
traditional healers. The knowledge about the therapeutic usefulness of plants is usually passed 
on from generation to generation. 
The major challenge to the use and development of traditional medicines is the lack of 
evidence of efficacy, safety and quality control measures. Guidelines have been developed on 
methods of evaluating the safety and efficacy of traditional medicines (WHO, 2000). These 
are aimed at strengthening the position of traditional medicines in health care. 
1.4.3 Traditional medicine practices in Uganda 
Traditional medicines are a very important component of the health delivery system in 
Uganda. The strength of traditional medicines is based on the fact that there is one traditional 
healer for every 200-400 people compared to one trained western health personnel to every 
20,000 people (Hibler, 2001). The indigenous traditional healers in Uganda include 
Herbalists, Spiritual healers, Bone Setters, Traditional Birth Attendants, Hydrotherapists and 
Traditional Dentists. There are non-indigenous practices that have been introduced recently 
and their popularity is on the rise. These include Chinese traditional medicines and practices 
like Acupuncture, Ayurvedic practices from India, Reiki, Chiropractice, Homeopathy and 
Reflexology. 
The indigenous traditional practitioners have been organized into several associations with 
registered members at the sub-county and district levels, coordinated by Cultural Officers. 
These associations are controlled by the National Council for Traditional Healers 
Associations (NACOTHA). This structure arose out of the need to make traditional medicines 
safe and weed out unacceptable practices like child sacrifice. Through· the council, 
government and non-government agencies are reaching out to the traditional healers to 
improve the quality of traditional medicines (Medlinks, 2003). The practitioners of non-
indigenous traditional medicines are generally not affiliated to any of these associations. 
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There is a difference in the understanding of disease between the traditional healing system 
and the western system. In the traditional system most disease entities are referred to 
symptomatically (Tabuti et aI., 2003). Although the disease entity malaria is well known, it is 
referred to by the same word as other fevers of different etiology. The plants used in the 
treatment of malaria are more or less designated to symptoms like fever, convulsions, 
headache abdominal pain and general weakness. Plant products more than animal products are 
used in' the treatment of malaria. It is common to find a smaIl medicine garden in each 
homestead although the majority of herbs are collected from the wild. A survey carried out in 
Bwindi impenetrable forests indicated that leaf material is the most widely used of all plant 
parts (Adjanohoun et al., 1993). Traditional healers, collect some of the commonly used 
plants, dry them and preserve them. When collecting the plants several precautions are taken 
in terms of season, time of the day, location of the plant and the plant part collected. People 
come to buy these herbs and traditional healers at times dispense them to people who present 
with health complaints. This service is extended to markets in urban areas, although 
commercial trade in traditional medicines is still at a low level in this country (Cunningham, 
1992)' 
The treatment of particular conditions varies extensively from community to community and 
even amongst traditional healers in the same community. The methods of administration of 
traditional medicines are perhaps as many as those used in western medicine. In the treatment 
of fevers the most common method is oral intake of plant decoction or maceration. The other 
important methods of administration include bathing with the extract, steam bath and 
inhalation of smoke from a burning plant part (Nalwoga, 2001). The parts used may be from 
one plant and in some cases a mixture of more than one plant is used, a practice that is similar 
to other communities in Tanzania (Gessler et al., 1995). 
The major challenges facing traditional medicine practices in Uganda is the lack of 
information on effectiveness and safety of the medicines. The lack of standardised methods of 
preparing and administering traditional medicines makes it more difficult to investigate these 
two important aspects of traditional medicines. There are researchers who have directed their 
efforts to help traditional healers prepare better, safer, and cheaper remedies (Hibler, 2001). 
Many traditional healers don't record relevant information that would help them monitor 
patients. There are no detailed studies to demonstrate the treatment outcome among patients 
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who visit traditional healers, but one minor study showed evidence of clinical and 
parasitological cure among malaria patients who took a traditional remedy (Bitawha et aI., 
1997). The continued existence of the traditional healers and growing use of traditional 
medicines in Uganda could be argued to be an indication of their effectiveness. Some 
traditional healers are still involved in practices like human sacrifice; these taint the image of 
other healers who are working to cure legitimate ailments like malaria. There is presently a 
nation-wide campaign against such practices (Nampala, 2001). 
Even with the current level of modem medicine in Uganda, people continue to seek traditional 
health care as before. Modem medical practitioners are continuing to recognise the traditional 
healers as a group that can fill gaps in their discipline (BBC news archives, 1999). By 1992, 
the two types of care providers had come together and established an organisation called 
THETA (Traditional and Modern Health Practitioners Together Against AIDS) that aimed at 
creating a mutually respectful collaboration between traditional healers and conventional 
health practitioners (Engle, 1998). This initiative intends working against other diseases like 
malaria. Traditional healing systems are dynamic and inclusive, and therefore we expect to 
see more incorporation of western elements into traditional medicine as the two systems 
continue to work together (Whyte, 1982). 
1.4.4 Adverse events associated with traditional medicines 
The notion that traditional medicines are natural and therefore safe is widely held around the 
world. This has led to increased use of traditional medicines without paying close attention to 
their safety. The incidence of adverse events in the use of traditional medicines is largely 
unknown. A few reports are now emerging with the increased marketing of herbal remedies 
based on traditional medicinal plants. Some herbal preparations have been reported to cause 
hypersensitivity reactions that range from a transient dermatitis to anaphylactic shock 
(perharic et aI., 1993). Agnus eastus, a plant with estrogen-like properties and taken 
commonly for the treatment of a variety of gynaecological problems, has been observed to 
cause increased uterine stimulation and predisposes mothers to miscarriages (Cahill et al., 
1995). St John's wort, a plant whose extracts are widely used in the treatment of depression, 
has been found to be an enzyme inducer of the CYP450-3A4, reducing plasma levels of drugs 
metabolised by this enzyme system and consequently the efficacy of many drugs (Roby et al., 
2000, Mai et aI., 2000). 
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The multi-system nature of the malaria infection and the short disease course reduces the 
chances, of detecting adverse effects of the traditional medicines when used. There is need to 
develop simple laboratory assays that can reliably predict possible adverse events and 
interactions of traditional medicines with other drugs. Some of the toxic effects of traditional 
medicines are predictable if the chemical constituents are known. The report of deaths due to 
cardiac glycoside poisoning from traditional medicines in some parts of South Africa 
(McVann et aI., 1992) calls for increased investigation into traditional medicines. 
1.5 Scope of the study 
1.5.1 Background of the study 
The rising incidence of Plasmodium strains resistant to the existing antimalarial drugs has 
emphasized the need for alternative malaria remedies. Almost all communities in malaria 
endemic areas have plants that are used to treat malaria symptoms. The potential of these 
plants as sources of antimalarial herbal remedies or lead compounds for antimalarial drugs has 
not been comprehensively assessed. In order for a traditional medicinal plant to have a high 
antimalarial potential, it requires evidence of efficacy and safety. With the current trend of 
combination therapy, favourable pharmacodynamic interactions with already developed 
antimalarial drugs like chloroquine and artemisinin enhances the antimalarial potential of a 
medicinal plant. 
The search for new antimalarial remedies has generally stimulated interest in traditional 
medicines and the WHO has declared it a priority area. The development of traditional 
medicines requires information on the uses and methods of preparation of these medicines. In 
Uganda an ethnobotanical sUlvey was carried out in which various plants were reported tO,be 
used in the treatment of malaria symptoms (Mubiru et al., 1993). Most of these plants have 
never been investigated for efficacy and safety and their potential as sources of malaria 
remedies is not established. 
1.5.2 Study objectives 
The main objective of this study was to investigate the antimalarial potential of some of the 
traditional medicinal plants pointed out both in previous literature and the recent 
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ethnobotanical survey. This involved looking for infonnation on the efficacy, safety and any 
potential interactions with other medicines. To achieve this objective the study focused on the 
following specific objectives: 
(1) To determine the antiplasmodial activity of extracts from the six study plants. 
(2) To study potential interactions between traditional medicines and some of the already 
established drugs, and establish the possible mechanisms behind these interactions. 
(3) To determine in vivo antimalarial activity of plants that may not show any in vitro 
antiplasmodial activity. 
(4) To carry out phytochemical analysis and characterisation of any principles from plants that 
possess anti plasmodial activity. 
(5) To establish the relevancy of our results to the development of Ugandan traditional 
medicinal plants as sources of malaria remedies. 
1.5.3 Rationale of study approach 
The investigation of a number of plants for antimalarial potential required simple and reliable 
high throughput assays that could screen a number of extracts in a short time. In this study, 
information on efficacy, safety and potential interactions was required for six plants. While 
infonnation from an in vivo system would give a high predictive value, setting up in vivo 
models is expensive, time consuming and has ethical issues. In this study, we decided to use 
an in vitro system and only the extracts from plants that did not show evidence of efficacy in 
vitro were screened in an animal model. 
1.5.4 Expected study outcomes 
This study was expected to provide information on the efficacy and safety of extracts from 
traditional malaria medicinal plants, which could be used in the development of herbal 
remedies or sources of lead compounds for antimalarial drugs. The information on possible 
interactions between traditional medicines and some of the drugs already in use for the 
treatment of malaria opens up a new area in terms of research and policy on the use of 
traditional medicines in malaria control. 
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1.5.5 Originality of the work 
In this study six plants that have never been investigated for antimalarial properties, based on 
the NAPRALERT (natural products alert) database, were selected from the plants that have 
been reported in ethnobotanical surveys of malaria treatment in Uganda. These were further 
confirmed in a meeting between the investigators and three traditional healers practising in 
three different communities in Uganda. The plants selected include Senecio disci/olius oliv, 
Senecio'stuhlmannii, Indigofera emarginel/a steud. Ex A. Rich, Aspilia africana (Pers) C.D. 
Adams, Cardiospermum halicacabum L and Momordica foetida Schumch. Et Thonn. These 
plants belong to four plant families: Asteraceae, Fabaceae (Leguminoseae), Sapindaceae and 
Cucurbitaceae. 
1.5.6 Description of study plants 
The plants S. disci/olius, S. stuhlmannii and A. africana belong to the family of Asteraceae. 
The plant S. disci/olius oliv is a common weed in gardens in parts of southern, central and 
eastern Uganda. It generally flourishes during the rain season and is scarce during the dry 
season. It is used in the treatment of abdominal pain and jaundice, both important symptoms 
of malaria. In the treatment of abdominal pain, leaves are squeezed in salted water and drunk, 
while in the treatment of jaundice, 250 ml of a leaf decoction is drunk once daily (Neuwinger, 
2000). This plant is also used a galactagogue and an antifungal (Adjanohoun et al., 1993). 
The other plant of the Senecio genus, S. stuhlmannii, is also called S. cydonii/olius O. It is a 
shrub with hairy leaves and fleshy stems. It is commonly found in homesteads where it is 
domestically grown because of its medicinal value. In the treatment of fever, pounded leaves 
are added to bath water, while 250 ml of leaf decoction is drunk once daily for the treatment 
of jaundice. This plant has been reported in the treatment of diarrhoea (Meikere-Faniyo et al., 
1989) and convulsions, both of which are common malaria symptoms. 
The plant A. africana is a shrub that grows wild in many grassland areas of Uganda. It is used 
in the treatment of wounds, acne, gonorrhoea, syphilis, pneumonia, headache, malaria and 
liver inflammation in parts of Central Africa (Rwangabo, 1993). A mixture of the root 
decoction with extracts from Pseudoarthria hookeri, Flueggea virosa and Vernonia 
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amygdalina has been reported in the treatment of fever. In the treatment of malaria and fevers 
as mentioned above, decoctions are taken orally (Adjanohoun et al., 1993). 
The Aspi/ia genus is perhaps the best studied of all the plants selected in this study. This has 
been as a result of widespread medicinal use and also the observation that wild primates feed 
on plants of this genus in a special way. Studies on the phytochemistry and biological activity 
of leaf extracts from Aspi/ia mossambicensis demonstrated the presence of oxytoccic 
diterpenes (page et al., 1992). Oils rich in monoterpenes and limonene have been extracted 
from the leaves of West African A. africana (pervez, 1993). Some of the already reported 
pharmacological effects of A. africana derivatives include anticoagulant properties (Hanna 
and Niemetz, 1987) and antibiotic properties, which are attributed to the presence of 
thiarubrine A (Rodriguez, 1985). 
A number of biologically active molecules have been isolated from the Asteraceae family, the 
most successful of which is the sesquiterpene endoperoxide lactone, artemisinin, isolated from 
Artemisia annua L (Klayman, 1985, Hien et al., 1993), from which a number of semi-
synthetic antimalarial compounds have been derived. The other compounds with 
antiplasmodial activity derived from these plants include the sesquieterpenes, zingiberene-3,6-
f3-endoperoxide and zingiberene-3,6-a.-endoperoxides (Ruecker et al., 1996). The compound 
Thiarubrine A, isolated from A. q[ricana, has antimicrobial properties (Page et al., 1997). A 
number. of compounds have been isolated from the Asteraceae family, but their biological 
activity is not reported (South African Traditional Medicines Research Unit database, 2003). 
The plant Indigo/era emarginella stood. Ex A. Rich. belongs to the family Fabaceae 
(Leguminoseae). This plant has been reported to be used in the treatment of rectal prolapse, 
swollen legs, abdominal pain and convulsions in children. In the treatment of convulsions (a 
common sign of childhood malaria) a root infusion is drunk together with an extract from 
Hoslundia opposita (Kokwaro, 1976). There are no chemical compounds that have been 
isolated from this particular plant species neither has the biological activity of the extracts 
from this plant been investigated, but benzofurans with antimicrobial activity has been 
isolated from Indigo/era microcarpa, a plant from the same genus (de moraes e Souza et al., 
1991). 
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Momordica foetida Schumch. Et Thonn is a climber that is commonly found in swampy areas 
in parts of central Uganda. This plant belongs to the family Cucurhitaceae. It has medicinal 
uses ranging from spiritual and psychiatric conditions to physical diseases. The drinking of 
aqueous leaf extracts of this plant for malaria treatment has been reported widely in parts of 
east and central Africa (Hakizamungu et al., 1992, Rwangabo, 1993). The other uses of 
extracts from this plant include the treatment of hypertension, ulcers, and diabetes, and as a 
purgative. These uses have not been investigated. 
Cardiospermum halicacahum L is a climber that grows near tall trees. It is found in tropical 
forests in central and southern Uganda. This plant belongs to the family of Sapindaceae. The 
plant is used in the treatment of cough, hyperthermia, rheumatism, lumbago, nervous illnesses 
and amenorrhoea (Neuwinger, 2000). Two glasses of a 12-hour maceration of aerial parts of 
the plant are drunk or used for bathing in the treatment of hyperthermia. In some areas, seed 
water extracts are drunk for the treatment of fever (Neuwinger, 2000). These traditional uses 
have not been investigated and there is no scientific evidence yet to prove that extracts from 
this plant are effective for these conditions. 
While traditional uses of many Ugandan plants are well known, there is hardly any 
information on their biological activity, safety and interactions with other medicaments. This 
study is expected to provide information relevant to the development of antimalarial remedies 
from these plants. 
1.6 Summary 
Malaria is a major world disease problem that is yet to be satisfactorily controlled. At present, 
chemotherapy is the mainstay of malaria control. Parasite resistance to existing antimalarial 
drugs is on the rise, extending to new geographical areas and affecting species other than P. 
falciparum. This raises the need for ongoing discovery of new, safe and effective 
drugs/herbal remedies for the treatment of malaria. Historically, traditional medicines have 
been the source of most successful antimalarial agents namely the quinolines and the 
endoperoxides/artemisinin derivatives. Although Africa has rich flora and fauna, it is yet to be 
tapped as a source of medicine. This study investigates the antimalarial potential of S. 
disci/o/ius, S. stuhlmannii. I. emarginella, A. ajricana, C. halicacahum and M foetida all of 
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which have been reported in ethnobotanicaI surveys and confirmed by tradItional healers 
practising in three different Ugandan communities. 
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Materials and methods 
2.1 Introduction 
The fact that traditional medicinal plants have a long history of use makes clinical studies the 
most logical approach to the investigation of their efficacy and safety. This approach is 
however costly, time consuming and has ethical complications that make it unsuitable for 
large-scale screening. Preclinical studies therefore remain important in the early screening of 
potential antimalarial plants. 
In this chapter we describe the methods used in the selection, collection, identification, 
phytochemical analysis, determination of efficacy and safety of six Ugandan traditional 
medicinal plants. In vitro assays were used to investigate antiplasmodial efficacy and 
interactions between traditional medicines and drugs commonly used in malaria treatment. A 
selection of plants that did not show in vitro antiplasmodial activity was screened for 
antimalarial activity using a murine model of cerebral malaria. 
2.2 Collection and identification of plant materials 
Three traditional healers registered with the National Council for Traditional Healers 
Associations in Uganda (NACOTHA) were identified around the towns of Masaka, Iganga 
and Mbale. A map of Uganda showing the location of these towns is shown in Appendix I. 
These towns have different tribal communities and were selected so as to include medicinal 
plants from at least three different communities. In a meeting with each of the traditional 
healers, the list of antimalarial traditional medicinal plants reported in the ethnobotanical 
surveys was confirmed. Plants, which from literature search had previously been investigated 
for antimalarial properties, were excluded from the list. The plants Momordica joetida 
Schumch. Et Thonn, Aspi/ia africana (Pers) C.D. Adams and Cardiospermum halicacabum 
L., were selected from Masaka, Senecio discifolius oliv and Senecio stuhlmannii from the 
Iganga area and Indigofera emarginella steud. Ex A. Richfrom the Mbale area. 
During collection only plants judged as mature by the investigators and the traditional healer 
who acted as a guide were harvested, and this was done during daytime. The first batch was 
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collected between May and June 2000; during this period most parts of Uganda received a lot 
of rainfall. The second batch was collected in December 2000 
and January 2001, a period that is generally dry and hot. For each specimen a shoot with 
leaves and flowers was taken to the Department of Botany of Makerere University for 
identification. The investigator with the help of a botanist discarded plants that showed 
evidence of viral, bacterial or fungal infection. Voucher specimens were air dried, allocated 
voucher numbers and preserved in the Makerere University Herbarium. 
2.3 Phytochemical analysis 
2.3.1 Preparation and extraction of plant material 
Traditional healers preserve plant specimens by sun drying. In this study it was preferred to 
air-dry the plant material at room temperature as it is more convenient and produces cleaner 
plant materials with less risk of contamination. The dry material was later crushed to powder 
using pestle and mortar. While water is the most widely used solvent by traditional healers, it 
is generally difficult to eliminate from the sample/extract. This has made water extraction less 
popular. in plant studies. Soxhlet extraction with alcohol tends to extract exhaustively but 
extracts only polar compounds, and involves boiling the extract with the solvent over time. 
Sustained boiling may not be desirable if one is uncertain of the stability of the active 
principles. Alternatively, extraction may be by successive extractions with solvents of 
increasing polarity. This is based on the solubility principle of'similia similibus solvuntur' 
(similar dissolves similar). This method does extraction and fractionation concurrently, and 
was used for all extractions in this study. 
Materials and solvents 
The solvents used for the extractions were hexane, ethyl acetate (Merck-Aldrich), methanol 
(Scharlau Chemicals, South Africa) and Millipore@ water. A mechanical shaker (Labcon 
Inc:), Rotary evaporator (BUCHl Scientific Equipments) and a freeze drier (FTS Systems, 
Stone Ridge, New York, USA), were used. 
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Experimental system 
To determine the yields, 15g of the plant powder were placed in 200 ml Millipore water in a 
I-litre flask, shaken for 24 hrs using a mechanical shaker at 125 revolutions per minute 
(RPM), and filtered using a 125mm filter paper. The extract was then frozen at -80 degrees 
for 6hrs in a lliter flask. The frozen extract was then freeze-dried at a vacuum of 50mmHg 
and temperature of -70°C. The dried extract was weighed and the yield expressed as the 
weight of water extract as a percentage of dry plant powder. The freeze-dried extracts were 
kept at room temperature and subsequently reconstituted and screened for antiplasmodial 
activity. 
An additional 35g of plant powder was weighed and solvent extraction performed as above, 
this time with organic solvents. For each portion of plant powder, hexane 300 ml was added 
and shaken for 24 hrs. The remaining plant material from hexane extraction was then 
subjected to ethyl acetate extraction and finally to methanol extraction. After 24 hours of 
extraction, extracts were concentrated by rotary evaporation using the Buchi rotary evaporator 
at 40°C and a vacuum of 335 mbars for hexane, 240 mbars for ethyl acetate, and 337 mbars 
for methanol. The yield was determined, as described above, and the extract stored at room 
temperature for subsequent antiplasmodial screening. 
A second batch of the plants A. africana, S. discifalius, S. stuhlmannii and I. emargine//a 
was collected from the same areas as the first batch in the months of December 2000 and 
January· 2001. The plant material was processed as described above and rescreened for 
antiplasmodial activity following the same procedures. For bioassay-guided fractionation, 
1000 g of dry plant material of the most active batch was extracted. During collection of the 
third batch, only A. africana was collected during June-July 2002. 
2.3.2 Bioassay-guided fractionation 
Fractionation of plant extracts before screening for biological activity improves antimalarial 
activity (Statz and Coon, 1976). Commonly used methods of fractionation in plant work 
include solvent partitioning and chromatography. In solvent partitioning the extract is placed 
in two immiscible solvents in a separating funnel. The different constituents in the extract 
partition according to their respective solubilities in the two solvents. This method is simple 
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and rapid but produces at most three fractions. Chromatography involves the separation of 
compounds basing on their difference in binding to the stationary phase. Chromatography 
techniques where used in the fractionation of extracts in this study. 
2.3.2.1 Solid phase extraction of the crude extracts 
Materials and reagents 
Solid Phase Extraction (SPE) was done using hexane and ethyl acetate (Merck-Aldrich). 
Methanol and acetonitrile was supplied by Scharlau Chemicals, South Africa. Silica and C-18 
SPE columns both of sorbent mass 109 and a volume of 70mls were supplied by Anatech 
Instruments, South Africa. 
Experimental system 
Fractionation of the methanol extract of S. discifolius and ethyl acetate extracts from S. 
stuhlmannii, /. emarginella and A. africana was done by SPE. Stock solutions were prepared 
by dissolving 400 mg of the extract in 65 ml ethyl acetate. The solution was sonicated for 
about 3 minutes to dissolve as much of the extract as possible, and then filtered using 
Whatman filter paper with 125 Jlm pores. The residue was allowed to dry and redissolved in 
ethyl acetate. The filtrate was then topped up with 130ml of hexane to make a stock solution 
of 7:3 ethyl acetate: hexane, and transferred into 50ml centrifuge tubes and spun at 13000 
RPM for 10 minutes. The supernatant was used as stock solution for SPE while the pellet was 
kept for the antiplasmodial assay. The mobile phase for all extracts was made up of hexane 
and ethyl acetate. Six sets of 800ml eluting solvent were prepared with the following hexane: 
ethyl acetate ratios by volume: 100:0, 75:25, 50:50, 25:75 and 0:100, together with 100% 
acetone to wash the column after elution with each solvent ratio. 
A silica column was first conditioned by elution with 100ml ethyl acetate followed by 100mls 
of hexane. The column was then loaded with 50ml extract solution (about 100mg, 1 % of the 
column sorbent mass) and the extract was eluted with a low vacuum. The percolate was 
collected and concentrated by rotary evaporation and subsequently tested for in vitro 
antimalarial activity. Using a vacuum of 0.5 Kpa, 200ml of the mobile phase at each ratio was 
used for eluting. The elutions were in increasing ratio of ethyl acetate. All the fractions were 
collected, concentrated by rotary evaporation and tested for anti plasmodial activity. The same 
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process was followed for all crude extracts, except with S. stuhlmannii in which preliminary 
separation was not satisfactory and a C-18 column was used with increasing ratio of 
acetonitrile: water as the mobile phase. 
In the fractionationation of S. stuhlmannii, 25% increments of acetonitrile to water were 
used, followed by 10% increments. A stock solution of the extract was prepared by dissolving 
400mg of crude extract in 65 mI of acetonitrile, and sonicated for 5 minutes. The solution was 
fIltered ·and the fiIterate supplemented with 130mI of MiIlipore water, to make a stock 
solution of 7:3 water to acetonitrile. This was then centrifuged and the pellet prepared for 
antiplasmodial screening. Each time 50m1 (about 100mg of extract, 1 % of cartilage sorbent 
mass) of the extract were loaded in the column and eluted with 200 ml mobile phase at each 
ratio, with the same vacuum as previously. The fractions were collected and concentrated by 
rotary evaporation to remove the acetonitrile. The water portion was then removed using a 
freeze-drier, as described previously. 
2.3.2.2 Further SPE on the crude ethyl acetate fraction of A. africana 
In order to isolate the active principle in the ethyl acetate fraction of A. africana, SPE was 
done on a large scale with crude ethyl acetate extract. The silica column was used with ethyl 
acetate and hexane as the mobile phase. The ratios of ethyl acetate to hexane were 0: 100, 
10:90, 20:80, and by progressive increments to 100:0. Pure acetone was used to wash the 
column as before. The extracts were prepared and the elutions were carried out as previously. 
The fractions were concentrated by rotary evaporation, weighed, and tested for antiplasmodial 
activity. The most active fraction was subjected to analytical High Performance Liquid 
Chromatography (HPLC) to check the purity of the extract. 
The 50% ethyl acetate fraction was subjected to more refined SPE, the mobile phase this time 
being prepared with 1 % increments in the ratio ethyl acetate: hexane. The mobile phase 
combination ratio started from ethyl acetate: hexane: 41 :59, 42:58, 43:57, and by serial 
increments to 50:50 and followed by an acetone wash. The stock extract solution and method 
of extract preparation were as previously. The elutions were carried out similarly and the 
extracts concentrated by rotary evaporation. The dried extract was tested for antiplasmodial 
activity and the most active fraction analysed for purity using analytical HPLC. 
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2.3.2.3 Preparatory high performance liquid chromatography 
The I: I ethyl acetate: hexane fraction of A. africana from the third batch was fractionated by 
preparatory HPLC. 
Materials and solvents 
A pre-packed semi-preparatory C-18 column (Haisal, 100 C-18, SIN 943692, Higgins 
Analytical Inc:) of dimensions 250xlO mm and a Shimadzu LC-lOAS with a diode array 
detector SPD-MlOA and a communications bas module, CBM-lOA, a guard column packed 
with C-18, 40J..1ffi (Bondesil guard column) were used. Acetonitrile of HPLC grade supplied 
by the Merck-Aldrich and Millipore® water were used in the mobile phase. Purity test runs 
were carried out using a pre-packed C-18 analytical column 150 x 4.6mm (phenomenex, St. 
Torrance, USA). 
Experiment 
The 1: I ethyl acetate/hexane fraction of the third batch of plant material was fractionated 
using preparatory HPLC. A stock solution was prepared by dissolving 20mg ofthe extract in 
1000J.!l acetonitrile. This was then topped up to 3000J.!l with MiUipore water to make a stock 
solution of 30% acetonitrile in water. Trial runs were conducted and an injection volume of 
200J.!l selected with a flow rate of 4 mVminute and isocratic run of 2:3 acetonitrile to water for 
8 minutes. The column was washed for an additional 4 minutes, during which the proportion 
of acetonitrile was raised to 100 % in the first 2 minutes and reduced to 0% in the last two 
minutes. The column was conditioned by having two runs, the first with I00J.11 water injection 
followed by 100J.!l acetonitrile. These runs were under the same conditions described above. 
The UV spectra of the various extracts were determined and the fractions collected in flat-
bottomed flasks. Four fractions F 1, F2, F3, and F 4, were collected between retention times, 2.5 
to 3.2, 3.2 to 4.3,4.3 to 5.2 and after 5.2 minutes. The acetonitrile was removed with a rotary 
evaporator. Water was eliminated as described previously. The fractions were weighed, and 
stored at room temperature for later anti plasmodial activity testing and mass spectrometry. 
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2.3.3 Characterisation of plant principles 
Isolates from extracts were characterized by mass spectrometry (MS) and Ultra violet (UV) 
absorbance. Mass spectrometry provided their molecular weights, which' were used to 
determine the molecular formula. The UV spectra were determined using the diode array 
detector of the HPLC machine. Mass spectrometry was done on about 1 mg of the isolate 
using high-resolution mass spectrometer or low-resolution mass spectrometer. 
2.4 Antiplasmodial activity of plant extracts 
The parasite lactate dehydrogenase (pLDH) assay was used in the determination of 
antiplasmodial activity of extracts in this study. The principle behind this assay is described in 
chapter one. 
Materials and reagents 
Culture medium used was made up of RPMI 1640 (Bio Whittaker) medium supplemented 
with albumax II (lipid rich bovine serum albumin) 25g1L, hypoxanthine (44 mgll), N-(2-
hydroxyethyl)-piperazine-N-2-ethanesulphonic acid (HEPES) (6grn/L), sodium bicarbonate 
(2.1 gIL) and gentamycin (50 mgIL). All the reagents were supplied by Sigma-Aldrich, South 
Mrica. The reagents used for the lactate dehydrogenase assay included: Nitroblue tetrazoIium 
(NBT) (l.96 mM) and phenazine ethosulfate (PES) (0.24 mM) solution in MiIIipore water. 
The mal stat reagent was made from triton (l mIlL), APAD (0.33 gIL) and TRIS buffer (3.3 
gIL) in MiIIipore water (Sigma-Aldrich, South Africa). Sigma-Aldrich, South Africa also 
supplied chloroquine diphosphate, artemisinin and D-sorbitol. Group 0+ blood was obtained 
from the Groote Schuur Hospital Blood Transfusion Services Department. A 7520 Plate 
reader (Cambridge Technology, Inc:) was used. 
Two strains of P. Jalciparum were used. The chloroquine-sensitive D 1 0 was derived from the 
FCQ-27, an isolate from a patient in Papua New Guinea (donated by Dr A. Cowman, Walter 
and Eliza Hall Institute of Research, Melbourne, Australia). The other, chloroquine-and 
sulphonamide-resistant KI; was isolated from a patient at Kanchanaburi, Thailand (donated 
by Dr D. Wallaker, University of Edinburgh, Scotland). These strains are kept in liquid 
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nitrogen in the laboratory of the Division of Clinical Pharmacology, University of Cape 
Town. 
Thawing of parasites. 
Erythrocytes parasitised by the two strains 010 and KI, respectively were transferred from 
liquid nitrogen to a 10m} centrifuge tube and washed three times with sterile 12% sodium 
chloride. Using a pipette 100f..l,} of fresh red blood cells were added followed by 50 m1 of 
culture media. The mixture was then transferred to a 250 m1 culture flask and gassed for 2 
minutes with 93% nitrogen, 3% oxygen and 4% carbon dioxide. The two strains were 
maintained in continuous culture (Trager and Jensen, 1976). Culture media was changed 
every 24 hours and whenever the parasites were in trophozoite stage they were fed with fresh 
red blood cells to maintain the parasitaemia below 10%. The cultures were synchronized 
regularly, and before each drug sensitivity experiment. 
Synchronizing of parasite cultures 
To each volume of infected erythrocyte pellet,S volumes of 5% D-sorbitol at 37° C was 
added, and allowed to stand at room temperature for 10 minutes. The culture was then spun at 
600g for 5 minutes. The level of parasitaemia of the red blood cells was adjusted to 2% using 
normal human group 0 Rhesus +ve red blood cells and the haematocrit adjusted to 2% using 
tissue culture medium. 
Preparation of the plant extracts and drugs 
Experience from our laboratory has shown that crude extracts with significant antiplasmodial 
activity have a 50% inhibitory concentration (ICso) between 2 and 25 Ilg/ml. Stock solutions 
of the crude extracts were made so as to have a dosing range of 1000 to 2.0 f..I,g/ml on the 96-
well plate. Stock solutions with concentrations ranging from 1000 to 20f..l,g/ml of plant extracts 
were prepared by dissolving the extracts in culture medium. For those extracts that did not 
dissolve readily, a solvent of 1 % methanol in culture medium was used. Solid phase 
extraction fractions and pure plant isolates required lower dosing ranges. The stock solutions 
were kept in sterile conditions at 4°C for subsequent testing. For chloroquine and artemisinin 
the initial concentration of If..l,g/ml was achieved by dissolving the drug in culture media for 
chloroquine, and methanol then topped up with culture media for artemisinin. 
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Lactate dehydrogenase assay 
A 96-well plate was used for the lactate dehydrogenase assay. To each well, 100 J..I.I of culture 
media were added, except in column three. To the third column, 200 J..I.l of the stock extract 
solution was added, using a multi-pipette dispenser 100J..l.l of the extract was transferred and 
mixed with culture medium in the fourth column, then from fourth to fifth leading to double 
dilution across the plate to the last column. To the first column, 100 J..I.l of non-parasitised red 
blood cells the haematocrit of which had been adjusted to 2% was added. This acted as the 
negative control. To the other wells of the plate 100J..l.l suspension of human red blood cells of 
2% parasitaemia adjusted to 2% haematocrit with culture medium was added. This allowed 
two fold dilutions to be studied, concentrations ranging from 1000 to 2.0J..l.glml, and 
sometimes lower, depending on the expected activity of the extract. Column two contained 
parasitised red blood cells without test drug, and served as the positive control. The plates 
were covered with a sterile lid and placed in an airtight cabinet, gassed with 93% N, 3% O2 
and 4% CO2 for at least 1 minute and then placed in a 37°C incubator for 48hrs. 
The plates were incubated for 48 hr to complete one erythrocytic cycle, which exposed all 
parasite stages to the drug. After incubation, 15 J..I.l of the blood suspension from each well was 
transferred to a 96-well, flat-bottomed microtitre plate containing 100 J..I.l of malstat reagent. 
Then 25· J..I.l ofNBT were added to all plates and allowed to develop for 10 minutes away from 
direct light. The plates were read at 640nm. The optical density of the first column (blank) 
was subtracted from the other readings. 
Chemical injury to erythrocytes 
To assess any chemical injury to erythrocytes that could be attributed to the extract, 100 J..I.l of 
erythrocytes was incubated with 100 J..I.l of the extracts at a dose equal to the highest dose used 
in the antiplasmodial assay. The conditions of the experiment remained as for the 
antiplasmodial assay. After 48 hrs of incubation thin blood smears were giemsa-stained and 
observed for any morphological changes using a light microscope at a magnification of 100 
times. The morphological findings were compared with those observed in erythrocytes from 
the blank described above (incubated uninfected erythrocytes without extract) 
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Data analysis 
The percentage parasite survival at each concentration was determined by expressing 
absorbance at that concentration as a percentage of the absorbance of the corresponding wells 
in column 2 (Infected erythrocytes incubated without drug, representing normal parasite 
growth). Results were compared using the non-parametric Mann-Whitney V-test. Percentage 
survival was plotted against the logarithm of concentration to generate a dose-response curve 
from which the ICso, was detennined being the concentration at which there was 50% parasite 
inhibition. Calculation was done using the prism graph pad V3. Each extract was tested in 
duplicate and the experiment repeated 2 or 3 times. 
2.5 Interactions between traditional medicines and antimalarial drugs 
Patients often take traditional medicines together with the already established antimalarials. 
There is hardly any information on possible interactions between traditional medicines and 
established drugs. A traditional medicine with high antimalarial potential should not impair 
the antimalarial activity of other drugs that might be administered concurrently. This was 
investigated in an in vitro system. 
An interaction might be investigated in two ways. One would be to determine the 
antiplasmodial activity of the combination of a known drug with active extract from the plant, 
and compare it with the activity of the individual drug. The other is to determine how an 
extract from the plant might affect the accumulation of the known drug in infected 
erythrocytes. In this study both methods were applied. 
2.5.1 Antiplasmodial activity of extract-drug combinations 
The lactate dehydrogenase assay was used to determine the in vitro antiplasmodial activity of 
the combination of a plant extract and the two drugs. To extrapolate the results to the clinical 
situation would require that the experimental dose range should correspond with therapeutic 
concentrations of the drugs. The ratios of the drug combinations should be as close as possible 
to those that occur in vivo. The normal levels of active ingredients from plants in patients 
taking traditional medicines are not known and neither are the concentration ratios of 
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traditional medicines and the established drugs. Investigators working on drug combination 
studies have chosen starting concentrations basing on the ICso. Ringwald et aI., (1999) and 
Gupta et a/., (2002) used starting concentrations 10- to 100-times fold the ICso. In this study 
starting concentrations of 7-times fold the in vitro ICso of A. africana isolate was used, and 
the combination ratios were selected arbitrarily, between 4 and 40 (ACWI to chloroquine or 
artemisinin, respectively. 
Materials and reagents 
The materials used in this assay were the same as those described before. 
Experiment 
A stock soJution of the most active isolate from the third batch of A. Ajricana, ACWl, was 
prepared to a concentration of 25 J.lg/ml. Stock soJutions of chloroquine and artemisinin were 
prepared at a concentration of 2 J.lg/ml. The ch1oroquine-sensitive D 10 and the chloroquine-
and sulphonamide-resistant KI strain of P. jalciparum were made up to 2% haematocrit and a 
parasitaemia of 2%. The wells of the first three rows in the third coJumn contained 150 J.lI of 
ACWI stock solution and were topped up with 50 J.lI of chloroquine or artemisinin stock 
solution. In the second tripJicate, 100J..!l of ACWI were topped up with 100 J..!l of the standard 
drugs, in the third row 80J.lI of the ACWI and 120J.lI of drug, and in the last, 50J..!l of the 
ACWI were combined with 150 J..!l of the standard drugs. Double dilutions and the rest of 
experimental procedures were carried out as in the screening of plant extracts described 
earlier. The experiment was repeated twice for all combination ratios against the DlO and KI 
strains of P. jalciparum and for the two drugs investigated. 
Data analysis and interpretation 
The interaction between two chemotherapeutic agents is described by comparing the 
chemotherapeutic effect achieved by the agents alone with that in combination. The 50% 
inhibitory concentration (ICso) was used in the comparison of the chemotherapeutic effects. 
The concentration of each of the agents at the ICso of the combination was determined from a 
plot of percentage parasite survival against the base 10 Jogarithms of the concentrations using 
the prism Graph Pad V3. Two methods are used to analyse drug combination data, one is 
algebraical and the other is geometrical. The algebraic method invoJves expressing the drug 
concentration at the ICso of the combination as a fraction of its ICso. the fractional inhibitory 
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concentration (FIC). The sum of the FICs of the two agents in a combination describes the 
nature of the interaction. In this study, we used the geometrical method in which 
concentrations of the partner agents at the combination ICso are plotted on each axis and a line 
joining their ICsos (Isobole) included. Both methods give similar information, if the sum of the 
FIC is above I, in which case the data point will be above the isobole on the graph, the agents 
will be antagonistic. If the sum is 1, the point will be on the line or close to it, and the 
interaction will be additive. If below 1, the agents will be synergistic, and the point will be 
below the line. 
2.5.2 Effect of extract on uptake oflH dihydroartemisinin eB-DBA) 
Artemisinin and its active derivatives are sesquiterpene endoperoxide lactones that bind to 
heme in the parasite (Kamchonwongpaisan and Meshnick, 1996). The drug has to cross the 
red blood cell membrane and pass through the cytoplasm, along specific pathways into the 
parasite food vacuole. Interactions with other drugs might occur at any stage from uptake to 
the heme-binding site. To investigate drug interactions at cellular level radiolabeled 
artemisinin was used. The use of radiolabeled drugs assumes that disintegrations per minute 
are proportional to the amount of the drug taken up. This study investigated the effect of a 
plant extract on the uptake of 3H-dihydroartemisinin by erythrocytes infected by two strains of 
P. jalciparum. 
Materials and reagents 
3H-dihydroartemisinin (concentration, 714 nm, molecular weight, 284.3 and specific activity, 
I mC/mI) was kindly provided by Professor Michael Ashton, University of Gothenburg, 
Sweden. Dibutylphthalate, Solubable and Scintillation fluid were obtained from Packard 
Bioscience, BV, Groningen, The Netherlands. A Tri-Carb 2100 TR Liquid Scintillation 
Analyser (Packard Bioscience Company) was used. Ethylenediaminetetra-acetic Acid 
(EDT A) was obtained from Sigma-Aldrich, South Africa. 
2.5.2.1 Specific activity oflH-DHA 
To determine the specific activity, 10 ~ of 3H-DHA was made up to 100 ~ with methanol. 
To three scintillation vials 10 J.ll of this solution was added, followed by 2ml of scintillation 
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fluid. To another three vials 2 mJ of scintillation fluid was added, as a negative control. The 
disintegrations per minute (DPM) of the samples was determined using a liquid scintillation 
analyzer. The mean DPM was determined for the three experiments and the disintegrations 
per unit concentration of drug determined. 
2.5.2.2 Effect of drug dose on the uptake of 3H-DHA 
This study aimed to use doses close to the therapeutic dose of dihydroartemisinin. In vitro 
systems however lack key components of the in vivo system; drug protein binding, drug 
metabolism and elimination. This posed a challenge in choosing in vitro working dose that 
could give clinically significant results. A study among children reported parasite clearance of 
97-100% after 24 hours of treatment with artesunate. In this study, the mean maximum blood 
concentration (Cmax) of DHA was 0.18 JlglmJ (Halpaap et al., 1998); this would be equivalent 
to an exposure of 2.44 x 10-4 femtomoles per erythrocyte (Assuming a haematocrit of 50% 
and that, 1 ~ of packed erythrocytes has 5.2 x 106 cells). Another study done by Na 
Bangchang et al., 1994, indicated steady state concentrations of DHA ranging from 36 to 60 
nglml, in six volunteers who taking 200mg of artemether orally, 100mg after 12 hrs and 
100mg daily for days. This would be equivalent to a steady state exposure of 4.9 x 10·s to 8.1 
x 10·s femtomoleslper erythrocyte considering the assumptions above. Consideration the 
effect of protein and cellular binding on in vivo drug availability to erythrocytes, this study 
worked' with drug ranges below those observed in the above studies (0.68-6.83 x 10-6 
femtomoleslerythrocyte ). 
Experiment 
To determine the effect of dose on drug uptake per erythrocyte, increasing drug 
concentrations were incubated with erythrocytes at 37°C. A stock solution of 3H_ 
dihydroartemisinin was prepared at a concentration of O.OOlnglJll and stored at 4°C. 
Erythrocytes infected with the D 1 0 trophozoites that had been synchronized 12 hours 
previously were made up to a 5% parasitaemia and haematocrit of 1 %. (These parameters had 
been used successfully in studies on the uptake of chloroquine and mefloquine in our 
laboratory). To six sets of triplicate appendorff vials, 1 ml of infected erythrocytes suspension 
were added, controlled with uninfected erythrocytes of haematocrit 1 %. The infected and 
uninfected erythrocytes were then exposed to 1 Jll, 2 JlI, 3 J.11, 5 Jll, 8 J.11 and 10 JlI of 
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radiolabeled dihydroartemisinin. The vials were incubated in a water bath at 37 ° C for 1 
hour. 
At the end of the incubation time, 100 ,.tI of dibutylphthalate was added to each vial and the 
vial spun for 1 minute at 13,000 RPM in a centrifuge. A corresponding set of sterile 
scintillation vials was prepared in triplicates. The tips of the vials were cut and dropped into 
the scintillation tubes. To each scintillation vial, solubable was added directly to the blood 
pellet. After 30 minutes, 50111 of EDT A were added and 5 minutes later, 100 III of hydrogen 
peroxide added. After another 30 minutes of standing, 2 ml of scintillation fluid were added. 
The scintillation vials were allowed 1 hr after which they were closed, labelled and placed in a 
scintillation counter. This experiment was repeated twice for each of the DIO strain and KI 
isolate of P. jalciparum. 
Data analysis 
The mean DPM of the two experiments was determined and assuming a linear correlation 
between DPM and drug concentrations, the specific activity determined above was used to 
calculate the amount of drug taken into an erythrocyte at a particular drug dose. For the 
infected erythrocytes, the mean DPM of the 95% of the uninfected erythrocyte pellet exposed 
to the same drug dose was subtracted from the mean DPM of the pellet; to obtain the DPM 
due to 5% infected erythrocytes. The percentage drug uptake was then determined as the 
average amount of drug taken up by an erythrocyte as a percentage of the amount of drug 
exposed to the erythrocyte. The data was analyzed using the Microsoft Excel and Statistica 
soft wares. 
2.5.2.3 Effect of lower temperature on the uptake of 3H-DHA 
To investigate the effect of temperature on the uptake of 3H-DHA infected and uninfected 
erythrocytes, an experiment was set up to determine the uptake of 3H-DHA at 4°C. A set of 5 
centrifuge vials was filled with Iml of uninfected erythrocytes suspension adjusted using 
culture media to a haematocrit of 1 %. Parallel to this experiment another set of 5 vials were 
filled with 1 ml suspension of erythrocytes infected with the D 1 0 strain of P. jalciparum 
(Parasitaemia adjusted to 5% and a haematocrit of 1% as in the earlier experiment). To these 
vials 3111 of 3H-DHA from the stock solution was added. The vials were incubated at 4°C for 
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1 hour. After stopping the experiment the vials were processed as described above. The 
percentage uptake of 3H-dihydroartemisinin by erythrocytes was calculated and the results 
compared with those ofthe earlier experiment carried out at 37°C: 
2.5.2.4 Effect of extract on uptake of 3H-DBA 
To investigate the effect of an isolate from A. africana on the uptake of 3HDHA a dose of 
2.04 x 10-6 finolslerythrocyte was selected, as it could allow detection of any increase or 
decrease in percentage uptake. Three extract doses; l50ng, 350ng and 600ng were chosen 
basing on the range of extract concentration found at the ICso of the combination with 
artemisinin. To 4 sets of 3 appendorf vials, 1 mI of erythrocyte suspension infected with the 
D10 strain of P.Jalciparum (haematocrit 1%, parasitaemia, 5%) was added. To the four sets 
of vials, 0, l50ng, 350ng and 600ng of A. ajricana isolate was added respectively. This was 
followed by 3Jll of3H-dihydroartemisinin from the stock solution. The vials were incubated at 
3rC for 2 hours. The vials were then prepared as already described above for reading using 
the liquid scintillation counter. The experiment was repeated 3 times for each of the D 1 0 and 
Kl strain of P. Jalciparum. The data was analysed using the Microsoft excel programme and 
percentage uptake worked out as described earlier. The non-parametric Mann-whitney U-test 
was used to compare the effects of different extract dose on 3H-DHA uptake. 
2.6 Studying the in vivo antimalarial activity 
A murine model of cerebral malaria was used to investigate the effect of two plant extracts on 
disease progress. The study was granted clearance from the Research and Ethics Committee 
of the University of Cape Town as shown in appendix 8. 
Materials and reagents 
Wild strains of C57BL mice, 6-8 weeks old were obtained from colonies in the animal unit of 
the University of Cape Town, South Africa. The P. berghei (Anka) strain cryopreserved in our 
laboratory originated from the Swiss Tropical Institute, Basle. Switzerland. DiethyJ ether, 
chloroquine diphosphate and Giemsa stain were from Merck-Aldrich, Steinheim, German. An 
automated cell counter ADVIA 120 supplied by Bayer was us~d for the haematological 
indices. 
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Experiment 
The experiments were carried out in the animal unit of the Faculty of Health Sciences of the 
University of Cape Town, South Africa. The animals were handled in accordance with the 
regulations for the handling of laboratory animals approved by the Research and Ethics 
Committee of the University of Cape town. The animals were housed in groups of five per 
cage at 22 0 C and relative humidity of 80%. The diet was made up of standard pellet diet and 
continuous clean drinking water. 
2.6.1. The natural history of rodent P. herghei malaria 
To study the natural history of rodent P. berghei (Anka) in the wild strains of C57BL mice, 
23 animals were obtained from the animal unit. The animals were put into 5 cages labelled A 
to E. Cage E had 3 animals only, the rest of the cages had 5 animals each. Animals in cage A 
and B were used as the control (uninfected) while animals in cage C and D were infected with 
P. berghei (Anka). 
The P. berghei (Anka) strain of rodent malaria, cryopreserved in our laboratory was thawed 
as earlier described for P. Jalciparnm; human erythrocytes were not added this time. The cell 
suspension was instead introduced intraperitoneally into 3 study animals each animal 
receiving 0.2 mIs. After five days the animals were anaesthetised using diethyl ether and 
blood from the animals was collected into heparinised bottles by cardiac puncture, the animals 
were subsequently sacrificed by cervical dislocation. Thin smears of the blood were prepared 
and stained using the Giemsa stain and the parasitaemia determined by light microscopy. 
Studies done indicate that normal C57BL mice of about 8 weeks have about 9.3x109 red blood 
cells per ml, together with the parasitaemia determined on giemsa stained microscopy, the 
number of infected erythrocytes per miIIitre was determined. Using Phosphate Buffered 
Saline (PBS) the blood was diluted to make a suspension of 5x 1 07 parasitised erythrocytes per 
miIIilitre. 
An infecting dose of Ix107 parasitised cells was then used by introducing 0.2mIs of blood 
suspension intraperitoneally into the mice in cages C and D. To obtain the changes in 
parasitaemia and haematological indices, one animal was sacrificed from cage B and D on 
days 0, 2, 4, 6 and 8 and 2ml of blood obtained by the method similar to the one used by 
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SaiRam et aI., 1997. Thin smears, 2 from each sample, were prepared from the blood samples 
and the rest of the blood transferred in a heparinised bottle for measurement of 
haematological parameters, which included: haemoglobin concentration, total white cell 
count, total platelet count and differential white cell count. The slides were stained using the 
giemsa stain and the parasitaemia determined by counting the number of parasitised 
erythrocytes per 1000 erythrocytes under light microscopy. The mice in groups A and C were 
counted and weighed, to determine the average weight and percentage survival on the 
corresponding days. The mean parasitaemia, average weight and mean survival time of mice 
in cages A (uninfected) and C (infected) was calculated using Microsoft Excel 2000. 
2.6.2. Antimalarial activity of M. foetida and C halicacabum 
Investigation of the water extracts of M foetida and C. halicacabum was carried out in two 
stages. The experimental design was similar to the four-day suppressive test, used by Peters et 
al., 1993. The first stage was a preliminary investigation in which 15 mice divided into 3 
groups; A, B, and C of 5 mice each were used. The mice were handled as described in the first 
part of experiment. All the animals in the 3 groups were infected with the P. berghei (Anka) 
as described earlier. Starting from day 0 (day of infection) the animals in group A were 
treated with chloroquine 10mg/kg twice a day, the animals in group B and C were treated with 
250 mglkg of the water extracts of M foetida and C. halicacabum twice a day respectively. 
The drug and extracts were administered in a volume of 0.2 mIs at each time by gastric 
lavage. The mice were observed for 14 days, during which, animals were observed for 
survival, weight change and development of parasitaemia. The mice were tail bled and two 
thin smears geimsa-stained to determine parasitaernia. The parameters taken on day eight 
were used in assessing the effect of the extracts on disease progress. The results were 
compared with those in the first animal experiment. 
The water extract of M foetida was investigated further. To do this 20 mice were divided into 
4 groups of 5 mice each and labelled A to D. The mice were handled as described earlier. The 
mice were transferred from the Animal unit to the Department of Pharmacology animal unit 
were they were kept for at least a week before the experiment was started to allow 
acclirnatisation. The mice in all the groups were infected with P. berghei anka as described 
above. The water extract of monnodica foetida was dissolved in PBS to make a stock solution 
of 150 mg/mt. The animals were weighed and basing on their weights doses of 10mg/kg, 
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10Ornglkg, 20Omg/kg and 500rnglkg were administered twice a day on days: 0, 1, 2 and 3 
after infection. The animals were monitored for three weeks, during which, a record of the 
weights, dying animals and parasitaemia were taken. The blood for the determination of 
parasitaemia was collected by tail bleeding and preparing two smears, which were giemsa-
stained .. The animals were also observed for any special characteristics during the time of the 
experiment. The mean parasitaemia, survival time and weight were determined using the 
Microsoft excel 2000 and analysed graphically_ 
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CHAPTER 3 
The in vitro anti plasmodial properties and phytochemical 
,analysis of six Ugandan traditional medicinal plants 
Phytochemistry and anti plasmodial activity of plant extracts 
3.1 Introduction 
This study investigated the antimalarial potential of medicinal plants of Uganda. To achieve 
this objective six plants Senecio discifolius oliv, Senecio stuhlmannii, Indigofera emarginella 
steud. Ex A. Rich, Aspilia africana (Pers) C.D. Adams. Cardiospermum halicacabum L and 
Momordica foetida Schumch. Et Thonn (voucher numbers WP1I2OO0 to WP6/2000 
respectively) were selected for investigation with the help of traditional healers. In this 
chapter we report the results of the frrst part of the study, which involved collection, 
identification, extraction, screening for anti plasmodial activity and phytochemical analysis of 
extracts from the study plants. 
3.2 Collection and identification of the plants 
Shoots of the plants, S. discifolius and S. stuhlmanni were collected from the eastern region 
of Uganda, 30km on Jinja -Iganga road. The plant L emarginella was collected near Mbale 
town on the eastern border of Uganda. The plants M foetida, A africana and C. 
halicacabum were collected 20 Km on Masaka-Mbarara road. All plants were collected 
during the month of June 2000 (wet season). The second batch of potentially active plants was 
recollected in December 2000 and part of January 2001, during this period, most parts of 
Uganda experienced the dry season. The plants were identified by a botanist· and voucher 
samples were deposited at the Makerere University Herbarium. 
3.3 Antiplasmodial activity of the study plants 
The yields and antiplasmodial activity of extracts from the first batch of plants are shown in 
Table 3.3.1a and 3.3.1b. Extracts with antiplasmodial activity of 50% inhibitory concentration 
(ICso) of 25 J.1g1ml or less were considered to have significant activity. The yields of the 
extracts, expressed as a percentage of dry weight of the plant material ranged from 0.8% to 
• John Tabuti, Lecturer, Department of Botany, Makerere University. Box 7062 Kampala, Uganda. 
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18.7%. For all the study plants water produced the highest extract yields. The most active 
extract was the ethyl acetate extract of A. ajricana, with activity ofICso. 9.3(7.7-1O.9)tJ.g/ml 
against the chloroquine-sensitive DI0 strain, and 11.5(8.7-14.3) J.1g/ml against the 
chloroquine-resistant K 1 strain of P. jalciparum. Except for A. ajricana, water extracts from 
all other plants did not show significant anti plasmodial activity. There was a positive 
correlation between the antiplasmodial activity of the extracts against the D 1 0 and K 1 strains 
of P. jalciparum (pearsons' coefficient, r = 0.9691, p=0.05) as shown on a scatter diagram in 
figure 3.3.1. This suggests similar antiplasmodial activity of extracts against the chloroquine-
sensitive and -resistant strains of P. jalciparum. The methanol extract of 1. emarginella and 
the ethyl acetate extracts of both S. stuhlmannii and S. discifolius showed significant activity 
against the two study strains. The second plant batch comprised of plants 1. emarginella. S. 
stuhlmannii, S. discifolius and A. ajricana. whose extracts had shown significant 
anti plasmodial activity. 
Microscopic observation of uninfected erythrocytes incubated with the methanol extract of I. 
emarginella, and the ethyl acetate extracts of S. stuhlmannii, S. discifolius and A. ajricana. 
and uninfected erythrocytes from the blank column of the 96-well plate showed no 
morphological differences after 48 hours of incubation. 
3.3.1 Yields and anti plasmodial activity of plants collected in the dry season 
The four plants collected during the dry season were extracted in exactly the same way as the 
first batch of plant material. Attention was paid to extracts that had shown antiplasmodial 
activity in the first batch. The antiplasmodial activity for the four extracts ranged from ICso 
values of 8.00 to 29.0 J.1g/ml as shown in Table 3.3.2. The ethyl acetate extract of A. africana 
showed the highest antiplasmodial activity with ICso of 8.0 (5.30-10.70) J.1g/ml. The yields of 
extracts from these plants ranged from 1.2 to 2.3% and were generally lower than those of 
plants collected during the wet season, as shown in figure 3.3.2. 
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S."01 ph ... r .... ~'j"" • 
• ,::' JA.~ "'nlil''''"",<>d;~ ;oCt!.l l} of lit(" "Itid pb • ..., (,,...I io,,, of A " 4ri~",.u ~l:lIi")1 Ih. 1I1b ~I .. ~jn of P 
J~I.;,...", .... V~lu .. :or. b~",~ .,n I" 0 nll<'rln' "hlJ ~.r.i.~ nuL In dU lllif~l~ ~"'I Il~nd"(ll .r!"Or Dr Ih ~ mun 
"orb~ oul ~I 'l!i~. co nf;'kh ~. i,",",~~l. t-!~ jllb~ I,~ ... nl f"'~liOn "hil~ ~c II I h., .f~IO". ,,~)h" 
T he SPE fraCtlonallons from Iht' ethyllcclatc t.~trael of A 0/1"/(:111111 'M:re more ac tive than the 
parent fracllons A more refined St'l " WU earned Olll .... ,lh 10"4 lRCremtn" of tth)'1 acetate to 
hexllue tn lhe mobile phase 11tc t I ethyl acetate to hcxanc fractlORallOn was the most actll'e 
wllh IC", of 1 6 Ilgfml The olhl."l" fracllOns had antlplasmodial aell\ll)" rangLng from ICoo, 5 
10 12 Itg/ml llM: pellet and percolatc dId nol show lnlrplilSlTloolal aCIl'"l\y and ale nOI 
Indicated in figure 3 "" To gel an idea tin the number of compounds that arc pre5Cm In Ihe 
IIIml Ictlve fractIOn. I nlg ofthc fraelJon wu dIssolved In 400 ~tI of HPLC wade acetonnnie. 
20 ilt of [hiS w~s run on an HT'LC anal}'llcaJ wllulln Fi~u re J 4 5 shOlvs I ehromalollram 
\\uh 01 main peaks correspondmg 10 compounds Ihal havc Ultra Violct (UV) absolbaocc .llhe 
wav"'cn~lh of 210 tIIl1 and e!tlled II rClel1l!un hnleS (Rl) of 10903. 12930" 14439 and 
t82SS l1llnuteS 
ThIs stud~ focused on demonstrating thnt Ugandiln traditional medlclllC$ can be a source of 
lead compounds for modern anllmalanal drugs To achieve rhr ~ ob)tttw~, we Klected tile I I 
fnlCtlOn of A, ujrt,"u/IO for funher fructlonatlon ThiS was done usmg SPE but Ihls time ",nh 
I",. mcrease III ethyl acetait.' to 11I,-nm, proportion III th" mobile phase The 42~. ethyl aceta te 
fiacllon to hexane was tiM: most actlv" wnh IUlI lplasmodlal actlvllY of I 8 )0 2 f'glrnJ as 
sllown In table 3 <I I \1JCroscopJC observatron of u!lLlltectl!d erythrocyti:S ~fter incub;u lon 
wnh tlus fr3ctioo o"cr 1m: <lS·hour period did nol show changes m morphology 
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ri ~ J .... 5 ' 11,~ ItPLC t"" UI,ul~r .. " , .... th( t : 1 ~'hlt ~fdll.:J~ .. n~ SPit ' r:.cl iDn .. , A. ,ifr;.:""". AhoUI 
!OI't ul III< (norl;"" .. 'a. 1".i<"<I~~ ~. ;. C- IH I"'~'p~,~cd ~"~Ill k~t '''''linn. A :::r-.di<:nl "''' of ~<cIHnn,.; re, 
.... ' ~f t...,m !1t% la Hilt"". ;01 ~ r.u~ 0( ""I/.,;n (or :'~ ",I nul" .. ~ 1IMl1. A Sh; m~d, .. LC·WA-~ ,,-;'h ~ 
"ioM a" .... ) d~" ... IIIr"ao "'~~. 
The rcst of the frllClioM ~ lower &I1tlr!asmodlaillCtJ\'ny than the parent li"ilCllon, 
A ~man amOUJ1l (I mg) of tile ,,~. tthyl attlate flXtlOlI was run Oil all arolylital tolumll, 
Fi!!un: 3 4 6 shows tile t hromatO!lrum of tile 42~. t lhyl acetate rract,on "lth a major peal a1 
retenllon Imlt fRT) of 8 102 mHlUld and D shoulder ill RT of8_369 mlfIJles are shown 
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ti: J. 4.1i. Th~ II P'LC t h ...... ~I<>l:,..~ .. oI ' b~ H % o.1 ltJ t ~tcl~lC: hn""" tr;t<llinn IIr A. "f,i<-~"". AtIl~1t snl'~ 
'" the ' ... e' ..... ""'" iftjn:teol for Ih .. non." ~r .... itDI no " "r ;""rr:l';"~ ~crl0nt'rik: "'alrr r ....... IO'{' 10 
100% fur It m,Mlllc3 on ~ " ... -pacju,d C ·111 ~ .. " I) , ic:at .... U"'R ...... IL"",d " ' " D lr Of ,,,, llm;n. ,\ Shi .. """ , .. 
I.C-III'\S ... j , ~ " diode • • ray 010'1..,' ....... " ..... d. 
The we/gill of the 4:2"1. :111\'1 acetalc: fraction was 6) rng AI leaS! 7 BmS of the p.uetlr 
fmellon was no! recovered 
3.:5 C lm r;tc terisatioll ofisol:ltrs frOIll A. n[rictlll l/ 
The Isolates were: characlcosed llsing mass spectromcuy aRd UV sp<:Cuoscopy The mass 
spectrum of the -12"10 ethyl aCclHtc IwlBle ,\ ,\2 , sho'led" molecular Io n peak at mil: milo of 
26<1 1357] The mass spectr:\ art: shown In approdi"( 1 and J, and the molecular formulae o f 
the Ions 111 oppcnd'lI 4 Tlus corre5pondcd 10 the: moil-culM we,slll of the 'solal~ and Ihe 
molL'1::ular rormul~ o f the isolate was worked out to b~ C,,1I:00. The presence of fifteen 
carhan aloms 15 t}'plcal of sesqlutcrpcn.:s The UV spectrum nr Lhlli compound IS shown In 
Appcndl~ .5 The l~'d of pUf'UV and qUHmity of isohue r~ov~red did nOI allow funller 
purifICation for ftnal structure duci<latlon USI ng NuclcHr M "gncllc RC!Onance (f\\ tR) 
T"bl~ J_~.I, A"'~'I:,,"""i~1 "~~i.il) ~"d }whl< 1'1 frnc~ID"' r,'",,, 51'!: 0' Ih~ I: ' . ,lIyl a<~Ial.: heun. 
tracI'o" of , ' , uin.otJIIIJ. on f~r1!Ier p.r,i,''''';«:: u,ml: 1 "I. '""rem.n" of •• h)' . rel, ,., heU"e in , he ".obile 
I'h~>(, rile f, .. cli ... , "·,,t~ , •• t~d A~"in" the I),,, ",.i" "r P. f~ldl"'m"" 
SQlit11Ih:l$t' fnKliOn A1I1ounl recoHretl lC~ ()Jt;lutl ) 
(0/.) long) 
rurolate 280 ~IOO 
" 
340 III ±24 
" 
OJO 18 ±<l2 
" 
641 78 ±I I 
" 
280 98 ±O9 
" 
"0 II 8 ±I I 
" 
410 1;13±16 
47 300 >100 
'" 
230 2100 
., 450 > 100 
SO 210 
" 
:! I i 
,':lrrnl fm eliOn 4864 36 ± 0; 
n", ["",um,. Dr. pero:l1l:r~c'$ or .,11)1 occwtr to 110."''''. '" mobIle phaso TI,e weit/lu life values or WI. 
e:o;P""''',,''l n,. Ie .. , .. Iucs 'If]! based on ',,"0 c_~per"''''llS earned om '" d"pIH""o, ,ho ~"d"d .rror or lh~ 
mean"~ wQlked o-nl at 9~% mnfldcncc: "".",,1 
In orde, 10 obtain ",ore of Ihe isolate AA2, aoother batch of pi am malerial was collected from 
the same loeatton In lh. month of June 2002 The material was processed as above and to 
fasten ,he separalion, the 50% ethyl acelale/he:oo:ane fractlun wa!i thts ume subJect<:d to seml-
prcparMory I U'LC The mnupllL'rnod;QI neuvny of the 500/y fractIon from ,be ,hird b~l,h w.u 
4 9 :to 8 ~g/ml An HPLC pUrity tl.'St "'as run on a semi-preparatory column using an isocratlc 
raHO of 2 J acetonol"le to water before collect lDn runs where done Two major peaks 
corresponding IJ compounds with relenlionl;me of2 883 and -1.692 minJleS were observed 
as shown on the chromalUgram in ligure 3 5.1 There were other minor peak$ corresponding 
to compounds with retention lime of 4 136 and 5 489 minutes Four fractions F, F/ F3 and F. 
were collected In between the limes mark~ on figure 3 5. 1 The fraclions were tested for 
antlplasmodtal act ivity against lh~ D 10 and K I stratn of P fu/crpllrrlJII The fractton Ft. later 
called ACWI ,n our laboratory and F} later called ACW2. had hlg.h anttplasmodtal aCllvuy 
agamsl Ihe chlorOlIUlne-sens;\;ve Dl0 and Ihe chlorol]uine-8ud sulphonamide-resislant KI 
:;trllinS of I' fmClp(lrlllll There was no evtdence of toxictty agamSI uninfected erythrocytes 
1'fI)'Il>rlIr"""'" ... 11 .... ""~..r """'9' "[fI"'" "'".. •• ,_"'-_________ _ 
The 1WO lsolares ,",'Cre IJIrc:ftsrUlsly mOle efiecr.ve agaUts1 the: ehloroquUle-n:515rall1 stram as 
mOI,n III table 3 S 1 The Isolare ,\C\\ I pan.cularly IS abour J umes more aeU\-e againsillie 
rCSIS1aril S1ram Ilran rht chlorO'!umt-5en5111'-e SITlIlIl. Companll!! ..... nh chioroqullle. lite Isolale 
15 effe<:uvc In a naITOl'er dose range as shown In fib'IJl"l: 3 S 3 
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~-I~. J .S. 1. Tbo IIPI.C ch ,·um.lP~nlm .... llot :141% clh, 1 ~«u 'r' hcc ....... (rAe ...... u( A. ",.Int"" from tbe: 
Ihlnl ,,,,, r il .... pI,,,,, "'~I rri.l. .-\bOlJI IJ IIIJ,I~ in ZIltlJ,lI "-1. i. j<-flod ~nd an i __ r.1II0 nlil '" Z,j arc' .... ilri .. 
'" ,,·~'o' ~, ~'"Un'ln r(lr" mmllies. ,\ C·] N 1"~i>a~kc.1 "m;·i> r.p~r"Gl')· column an d Sl"",~d~ .. l.e.l0AS 
,"Ih. diO<lr ~rr~y dCI«tDr "'en- .. ,cd. 
T~hk J.S- l Anlil,I;u,nodial ~< rMrJ and j ldd, of lra rriom 11, (ACWI), 11,. r , (ACW1). r . (~olarc.; tr .. n A. 
"i n'at'''' )' ~rt.",.si ~l. and < hl~""I~I"" ~~~i n.r II .. < hlo""I~ine-.., ,, .;r ;'. IHII and II, . <h!Qrfllluh.e- ~ a d 
... 'fou,n"Io:-...,II ,ru r " 1 .Ir.ln. "r P.julc;,n.rum. 
";,lrarIlU,"ljg l'f,·r:f,UlIgt Ie ".. lIll-llIUSI U III !!I'1I lu 1( '-\01 ~,niu l t h. t . 11 IIln 
Yil'l.I (11#' 1111) 1i,!:},,,l) 
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,\ 0\ 1 ( f,) 0000)6 I SI (I 21·1 81) 056 (0 26·0 86) 
AO\' 2 (F, . 00001' I ~O(I D-167) 112(0~2-ln) 
F, o 00().I2 1155(91-140) 1435(1170-1700) 
F, o OOO~S .100 . 100 
Art l'-misirrjrr 040-060" o ().I) (0 ().I2- ().I4) 0017(0016-0017) 
Chlor"ori llille NIA o 102 (0 032-0 In) o D ol (0 1001- 564) 
l'U 1"1'111 rrar_Iirm 000360 490(011-57, NID 
NID Imlu;:;uetI 11uI1IN: ~jXllmmt "-U "'" done "blk NJA dollCllC:'l n ........ < no( .oppIigbk Y,eld!; .. < tw.:d "" 
0,10 t)<jXllmt"'u ' Y,dd uill!1<:""'''II' fron. Ih. Icr. .... 0( Chi,..,., Arf._, ..... "" ...... L by ba:roe ~Ir:oa"", 
(b"KI~ 20(2) V~lu¢$ 0( IC~ ~'c b:ti<id '"' h.O ~"rIC''' li dCIte on 1lupI1CII., ounrhtd .. rIrf 01" IIor; mc:In 1 ... 
bee .. "",,,~c:d 0111 ~I 90S·.·. conrrde"ce '111"'";11 
To che<:k the punty of the fraCiIOlls F, (ACWt) and FJ (AC W2). a punty run was earned OU t 
under the 0.11111'. condulorn: as used '" icm' ·prcparatOfY dUOIIlalograpny. The figures] 5 2 
and 3 5 J thow re1aI,~cl)' pure Iwlatc5 eJUllng 8t RT of2 !o4l1ltlU1uteS fOf ACW I and 4 6-12 
nurmtes for :\ rW2. The othO!f fracttons II ere I\()( tested for purrty u they sfKr,r,'ed lo ..... er 
allliplasmodial Dettvlty, Lo ..... ·reso/tJlion mass spectrometry of ACW I Indicatcd a molecular 
iOn of mUs/charge ratio of 211 IS dlOWI1 on the mass spectrum in Appendix 6 The UV 
spectrum of ACWt IS attached In appendix 7 The compOund AO' I ' .... s ditTO!fatt from ,\,\ 2 
earlier isolated. 
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3.6. Ilis(" ussilfn 
ThIS study shows thai e.,«ra.:15 frOin Ihe: planlS S. dl!.cljQ/IU.r. S .~lIIlIflllllllmi.l. e1/l"rgmelfa, 
and A ojr/{;QlI(J baYI; 51grnlil;3nl anliplasmodial actlvlly For all the four plants sigl1l flcam 
activity was obsc" .. ed wnh ethyllectale and methanol C.XH1'ICIS Going by the soIubLllty 
prlllcipic of' S!nular dissolves simililf' this finding sugw:su IMI conSUluelllS of these plants 
responSIble for the allllplasm()chal acti..,ty are generally polar compounds TIle aqueous and 
mtthanol e..~racu of A Cl/flWI1Cl. the plant "'1th the: most activc antlplulTKxhaJ c-"(tract have 
been reported to possess antiooctefllll aCIi~ity (Macroy and Cline, 1990). suggesting that 
constituents ofthl5 plant have broad-spectrum anunllcrob,al properties 
Surprisingly. water extlllCIS were generally less acttve.. ~t trndilioual healers reported usmg 
w~ter decoctOOCl$ and macellluons In the: treatment of malana symptoms It IS hOW~'YCf 
apparent. from the YIelds of the water e:<Trnos III ThiS study that WOJtl.."f lends to extract more 
compounds. thIS could have I dilUTing effect on lhe BllIlplasmodilll activity of the ':'"(UlICIS A 
possibiluy of 1/1 .·,/ra BntBgomSffi amongst tilt: compounds cannOt be ruled OUt as wen If thiS 
wefe the case then the poss.bllity of seleeu\'C absorpllon could lead to 1/1 ~11"tJ efficacy when 
"'lIt~r decoctions and maccratlOM are used In tradltloNI medicine 
Sti.ldy plams were screened against the chlofO(jUine-scnSltwc 010 and lhe chloroqUIne- Ind 
resisTant-n:.si$tanl K] stram A poSIt"'C correlallon wu ob$tr\-<5i bctwte!1 the aCtiVity of plant 
exlraCTs againSt the tWO strams (Pearsons ' coeffiCient, r-O 967. p..-o OS) and no slgJuficant 
difference in Butiplasmodlal actlvlly of an the c."(Iracts agamst the two Strains This findmg 
shows that cross-resistance between chloroqume and traditIOnal medlCl1lC$ docs MOl e:(iJl II 
phenomenon. wilich can allo ..... herba l remedtcs based on lradJllOl13] medlCl1lCS to be used In 
Ihe treatment of bot h chl<lroqullll:.-~nsit ,,·c ard ·res,Jl3nl !Mlaria. 
It \I'i\S obsc,,·l-d thut plants wllecled during the \\"et season had better yield~ tluln Ih.o§e 
colleCTed during the dry ~ason l:.J(tr~c" from the plams f elllf.ll1;/Il/d/a and S {/I,MmWllli, 
had bellCf anllplasmodlnl aCIIVlt)' during the dry se85()11 thall the .... ·I .. t season Smc;e chemIcal 
constituents aU: responsible tilr the anllplasmodlal activity of plant extracts. It 1$ logical 10 
concludc that the c h~mlcal compOSItion of titcS\! pl~nu vaned dunng the two seasons ThIS 
"nplles tllCre arc vanations In plunl met .• bohsm "","h 'Olallons. whIch also explainS the 
e"\:ISlen(C of ,\ ,\2 . ,\ C WI and ACW2 In dlffercm pl8111 batches ThiS IS in agreement lOoith 
the cather obSCfVdllOIlS. Ihal plants do\VI1 rcgulate ml1nbohsm III re~ollsc to 51 ress (lioekstra. 
el (II. 200 ! Howe lind Schllnuller. 2002) The VJrIOliom III )',cld5 has also been obSCl'ed 
WIth ."emi,mlli. an Bl1I lmalanaJ isolate from Artlllmill. (111111111 L. whose yields \"ary wuh 
seasons and even aflL"f one mght of stressful wc.1lhcr (\Vallaart 0;/ lIf.. 1999) IncldclI1 ully Ihe 
~"anatiolls III artl:llllSll1In ytdds have been obscrved even under highly controlled growth 
c;tllldlllOn$ of II WillI/II L (Llu Itr (,I .. 2003) These ob$erntions nllS': the 11t.'Cd for 
eon5lder~tlon of !!Cason when (ollc(IIng tr~dlllonal mcdl~lnal plallls It is probable th:tt more 
predictable Yields and anllplasmodlw aCllvllY could be: obtained from ~lanL~ grown under 
conHolled conditIOns than tllose growing In the Wild 
Fracnonatlon of e.XlrllCI$ from Ihe plants. I. o'tI1<1rglllel/a and S. dlscifoh"s did not result Into 
any IOcrease In antlplasmodlal activIty ThiS 5U~l!StS thaI the observed unllplasmodlal 8Chvlty 
IS due to a combmallon of plont constituents fhe concept of synergy 111 :reatmo:nt of malana 
IS e~emphticd by the Widely ust:d slllp!tado~,"dpynmo:thamInC combination, together "lIh 
c:ombinalLons Ike 5ulfamonomcthoxlne and 5· f1l1oroowtate. which art still e.~penmenlnl 
(Kim . • ~I al. 1998) The eXistence of synergy among trdlllonal mediCines is ho .... cver casy \0 
Imagme going by tile Wldo: spro:ad use of plant colllbinations in malana l1eatmenl (Gessler el 
( I I. 1995) T hae IS yet no experimental L"\idencc of synergy among anllmalanal traditional 
medicinal plann and this slUdy provides Indlre:ct o:vldo:ncc T he tact thaI the anuplasmodlal 
acllvlty of some plams cannot be Improved by frnclionallon suppom Ihe possib ll ily of 
dcveloping hertla! remedle, for trealmen t ofmalarJ8 ,",tead of the widely Ul rgelcd lsolalion of 
lead compounds 
The plants A . ttfl'lCWW and S .. llIIhlmUllllli belong to tanllly ASlcn/f'O'ffl'. ThiS is the fanlily to 
which arli.'misill (//1/1'/(1 L belongs. a plant (rom which thc endopO:f(l.,idc se:lqullerpene lactone. 
artemlsimn was i.<;.I)I~to:d FraClions from both these plants had IlIgh antiplll.<;rTIodiol activity 
Fractions from S. .'//1"'",allllll however, caused haemolysis of unmfe<:tei erythro~)1cs at a 
dose of IOO)I!,tIm1 BesslS, 1973. reported a number o(chenncal compounds that can cause 
haemolysis. theSe mclude saponins. bile salts. fatly acids and lecithins ThiS could be 
allnbuted to the pro:sence one or more of these compounds in the trru;tJon.. SInce the 
mt:<:hamsm of bacmolysis III ,'lIra Involves damagl.' of Ihe clythro(;)1e celt membranc. JI is 
possible that thi, (raction could as well be lo,ic 10 other mammalian cells 
~lore refin~'d scpal1ltiun of the A. ajric(u/l' metion from the second planl batch lead 10 the 
isolation of AA!. c!taractenscd to be a sesqullerpene T he tlilfd plam batch of A. ajnmlla also 
)'ieldcd eQually activo: compounds. ACW I and ACW2 Ihat could be scsquJlcrpenes Tho:sc 
compounds arc effeclive against both the cldoroquine-senslli,'c and e110rOl]umc·reSJS1Bm 
strains of ,> i"IC'I!ll/"lun although they act withm a narrower dose range compared 10 
c1~OI"OC]ulne Structural moditicallons can improve the antImalarial actJ\'ity of these 
compound~ Since the isolation of arteml$inm, scsqluterpencs are continuing 10 be recognised 
as a compounds ,,"uh anllmaLuu.1 poId1.tial t opes tl III 1999, has also allributoo th~ 1II1'/Inl 
IIflllplBsmodlal acti\1ty of the \-oI~lIle ad ITom Ilroia SlIrIIKmU!IIM' to a sesqUlleflIC'tle 
nerohdol, adding to the IISI of anll/mllUlal 5l'5qullerpencs 
The plants. C hahcac;abum and AI joel/ria did I1(It show all)' /II \'lira antlmalanal Deu~ilY 
There are a number of po~ibi!JIII!S Ihal e",plBLn this re$Uh E"'Il'aets from thue plants nlly be 
Inacuve, in which case Ihe plam does nOI have all~ Intlmalannl aell\'IIY 11,e extracts may be 
fiC!lIlg as pro-drugs III winch elISe they are effe(u\'e only In an 1/1 "11'0 syslem 01 the extracts 
m~y act by enhanCing lhe Immun~ sySI~m The WIde spread u)t of these plants calls for 
funher IIlveslIgalion of Ihelr anumalanal properties USIIIS an //I 11\'Q system, whICh IS reponed 
In one oflhe ne~1 chaplers Ofl h,s tepon 
While Ihe ISolation of active p,,"clples WJ$ ~uceessful, the linal elucldauon of the struClures 
was not particularly complete due 10 Ihe low yields of the IsolateJ The \'IIrialtOllS 111 plml 
pnnclples overtime cot\tnbuled to lht~ as well. as the c.o llect lon, extraction and fract tonatlon 
of plnnt matenal from the Ilurd batch Isolnted difrercnt compounds from those Isolated earher 
uSlOg the same methods The extractlotls III thiS study \\cre done by \\IlIler e)(lr~CIIOn Dnd 
sequenllal orgame extraction These mClhcxh Bre nOl eMcl ly the same as Ihose used by 
tradlhol~'l bealers TIns MUdy therefore does 1I0t fully replicate Iradnional healers plllctices 
but uses a scienltfic approach 10 tnterpretlhe practices oft radnionnl healers 
The Yields reponcd In ,his ~t udy arc due to a single e~nr:ct ion The rewlts would have wven a 
better picture If rcpc<lled e:>.uacllons were cDrned OUI on lhe sanle balch Some aspects oflhe 
plant mlCrohabttat. may IIOt ha\'~ been put Into considcrauon dunng plant collecllon such 15 
ndses and uplands these might han' coaunbuled 10 Ihe \'anauoos to yrelds and anuplasmodtal 
actlVtlY 
An III \'Ifro anllplasmodial assay was used to les, for anufTlalanal effICacy Whlle.t IS Imm'lI 
th.1I Bli known IlJllimalan31s have III I'llro DC!I\1IY, many compolJllds wnh III I'llro ~CI!""Y may 
I10t be effecllvc to mahm treatment Th,s could be a result of unfa\'ourable phanrocokmetic 
propentcs such as poor absorption of the extract, restricted dl5lnbulion. rapid mctabohsm ond 
rupid e/mllnallon of the prilXlplcs_ The m '1rm antimalarial assay llIJ.y thcrefOfe 001 be a 
perfect prediCtor ofaoumahlftJI potential 
In thll $mdv we usessed the. C\o1otoXICII)' or e:l;lraCl$ quahlatn-"cly. b)' SImple hghl 
mlcrosclJp!c observailOn or umnfected el)1hroq1es that had been IIlcuhaled Wllh Ih" c~lracts 
ThIs approach has been u.sed 10 assess Ihe IOxlCuy of other compounds (Fisther. tl til. 200J. 
\\~ nskl I!I 1'/. 1997) btu not '" the dlsco\ery of malana remedl\:! The .. hanllC$ III I:I)'throc.yte 
morphology under lliem5a-slallled light mICroscopy and electron mlO;(oscopy follo\\"1II1I 
~h",nllcaJ '"Jury are d~ribed b)' Bessis. 1973 ThIS method lias the adHlllIage Ih:1I the 
ul1.nfected erythrocytes can be IllCubated Wl lh lhe Cl(tract 00 the same %·\\cli pbtt' as Iht' 
anuplasmodlat assay. In lile seal"l:h for sImple and aCtUnlle methods Ofa.sse5SIIlII q1010XOCUy 
of anumalanal plant extracts. Ihis method can be developed fUl1h~f .nd validated [Of 
qUDl1l11atIVe asscssmem 
J.7 Conciusioilli 
Extracts from shoou of the plan ts S. d"',-I/O/Ills. S .. ,w""m(JI/llli. / i:/IlfJr}:/"t:I/II, and A 
tlfflcalK! hal'e a sogrulicant ill "11m ~ntipla.smodlal DCI,~ily The c.~tI1lCIS from the shoots of thc 
plant! C ''''/M/tt/hum and '" f(J;:lld" have no III \'11m anumalanal a~t,~i ty Gencl1IlIyextracu 
from all the piantS lICreencd dtd not show emu-reSIstance \\llh chloroqUine Thl! I!thyl Dct:tal ~ 
e:c.tract from the plant A afrlcall., /lml belong~ 10 lhe f3Ulll)' AIII;TlIci:OC had the best 
anllplasmodial actl11ty, WhiCh 15 due 10 lile pr~nce of anhmDlanal sesquuerpeoes This plam 
can se~ u a sotll'l:e oflead compounds for the dc\."e!opment of new anllmalanal planlS T ile 
sludy liso f"e','ealed Ibal )'H!lds of l'X1ra~ts and Ihl1r ~nl1pla.smodial actil'uy vaned Wllb season5 
10 SOnle plant .specIes. a Sl1U3l1on that requires tile Opllml!la1l0n of the cond.uons of harvest 
and UUllctlon to hale good ~Iclds Thl5 study indicates thai Ugandan IradJuOIl.1l medicines 
hal'e • high p!MenllaJ for the. productJon of lead rompounds for the development (If 
anhmaillnals and herbal remed,es 
CIIAPTER .J 
Interae/iolls be/weell trmlitiollal medicilles alld (wlimalurilll drugs: 
combilllllioll of A~1,i/itl afr;cmlll extract 11';11, ellioTOtl";IIl! alld 
tlrfe/llis;,, ; /I 
·U Introducti on 
Son~ of tlte p311elltS wlio lake lradu,onal medicines for the tre~unent of malana end up In 
hospitals wltere antlmalanal druJjs are prestnbed "These pat lcms may elld up u!lung the tWO 
mediClitioll5 COllcurrcmly ImL'flICll01\$ bcl\vCl:n tradluonal mr:dltI1H,~, and some of the 
commonly l1sed antimalarial drugs have Ililt been reponed befo re The chemical prnlClptes 
responsible for the. anllrnalarlll ell~1 In trad lllOllal medicmes are III mOli! ca5CS unknown, 
makulg II Impossible to predICt phalmacokilleuc and pharmacod>1lumlC IIller-aCUOlti wllh 
OIher medlcllles 
TIlls sludy used an lsolale ,\ C\VI from A ajncul/o 10 invesl 'l!ale JI05Sible pharmncodynanllC 
I1lIerlCI'OI15 belween chloroqUine and al1emlSIIIIII. This lsolale had been foulld 10 have 
anllplaSlnodll1 aCU\1ty of S~'. mhib'lory concentration (Ie'll) value of IS IO ng!lnl and 560 
ngfmllll\amst lhe chloroqullle-selWl"'~ DJO and chloroquine- and !llIlphonamide-resistant KI 
Slrllll15 of " jolc1lJUfltll' lespo!CII\'Ctv Two d,UilS. anem,smin and chloroqume were uscd 
agatnst 1m: t lV(} strains In rlus chapler we: repon the 'l1hplasrnodial activity ofchtoroquint 
.nd ancmts.min In COlllbtnallon .... nh lhe exltllCl ,\ C \\ 1 alld Ihe analYSIS 10 determine the 
lI<llUIC of the Interacllon belWeell the I\\'O drugs Ilid rhe e'macl The second pal1 of rhls 
chaplCf rcpon s the characrenstics of cellular uptakc of tnated dihydrolttemlSlnin ('H-Dl·IA) 
by I' j alcll)(/I1J1II Infected «)1hrocyu:s and how II '5 affecred by die Isolate , AC \\' 1. In bolh 
studIes efloru were made 10 use c!utically relevant doses Drug p,otem and cellular bmdulg, 
drul! tlll!thbolism, and ehnnnallon arc key componenls 11/ l'IIt) thaI ale not reproduced fully III 
11/ I'iff(> systems I" ~I/ro models generally use low haemalocnt and conI rolled parast!aeml8 
that require the usc of lower doSC!! 10 oblltll clulicalty relevam results 
A combination stud)' of lurlmalarial drugs by Ringwald IH uI , (1999) used slmmg doses 
raog'"g from 5 10 20 rllltes rhe Ie ", ThIS was used III selectIOn of lhe w\lrk,"l:I doSA.' range in 
thl~ study The combullilion rulO5 used m Ihis srudy wele selecled arbmanly as there is no 
tl\fOltllnllOn 011 the possible COtlCtntraLlnn raltos achie..-ed In blood \\hen plant c:.I:lrncts arc 
used togelher w,th anrllllalanal drugs. til the rreatment o r malaria Details of matenal$ and 
melllOd~ IISed havc been descnbed lit chaprer two 
-' .2 Alil iplas modilil acthcity or extract-drug com lIinations 
The dose and comlllnallon ranos or e:'(lfaCl t\CWI , and the two druBs anernlSlrun and 
chloroquine are sho\\n In Table 4 2. I The rughest dose or ACWI used was 6 lintel liS IC", 
agalll.'>1 ,he 01 0 slrain and 17 lunes the IC",ag:unsl the Kt 5mun I'or both chloroqume and 
Bnerlll5lnm, the lughesl do,sc, ranged between 2 and 20 limes Ihelr rl.'Spcclwe IC,. aS-IIlSI the 
1'I<1$lIIrKimm strains used III tile Study 
T. "I~ ~.l. l C""f UI ... "I .... ~ ,..,d rombill~lioto nolion or lI'r UII"Xl. an~ ,"" 10 .. , ullm~l>ri~' "nol:> 
(thlomquin. an" a"m,isjllin) UStd ;lIllot )Iud,·. 
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The rc~ or AC WI .nd anemi51RIR have heel. \1;Orked out 10 be 1510 and 43 Rglmt 
n::sp«:tively a!;atf\S1 1he 0 10 5UtlIR or p, foltrpcmrlll The concentraltons of ACWI al the IC}II 
of aJi SlUd)' comb,nallons are lower than liS IC~ as shown 111 tablc <I 2 2 The conccntratlons 
of anerlll511un at Ihe IC}O arc genernJly higher except at 37 6 
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Geometrical analpu shows datum j)OI1lI5 for lhe rOOf combmation ratio, above Ihe lsobole as 
shown 111 figure 4 2 1 This suggeSislhillthr e:<:lract AC\\ I, from A Ilfm:t"1l1 anlagol1lS(!J Ihe 
antimalUlal ad,"'t)' of artemiS/run agalllSl lhe 01 0 $lmm of P fitl,/ptJTum 
T"bl< ~.U .\a. itlla!m .... iaJ xli"i" pf ACWt ift rombi""' ..... ,.j,h .n~m"lfttn a~"; ".,I .... "t ~n(ft ,or P. 
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TI,~ Ie .. ... Iues ~'" b:lso:d 01' hili ~,n""'u C:lIl lcti 1IlI' .n dupllG1lC and 5I~.lIllld ell'lll 0(1111: mCOIa o::rIooLllcti 
:1\ 9~'" Wflfid<:na mlon'lll 
1'he IC IO of ACW I Bnd arte"UStnln ha\"c been ... orled 001 10 be S60 arK! 17 nglml respecll\dy 
IlgaIUSI the KI Slmln of P fi,kll'un,m The concentratIOn of AC\\ I at Ihe ICIO deaea..o;es u 
Ihe proportion of artCl»lSl nlO Ilicreases III Iii .: eomblll31 iun, Wllh VlI.!Ut-S belo" Ihe Ie", The 
colICentl'lUon o f Irtcnllsuun gent'fllily Increases 
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h= ~.l.l bClbulo~r~.., of I,", ;1I1" '1I<Iion l><"1",'t'a ACWI ud ~"t",bill'n a~,"" 1M "I .1,.,.1. of P. 
juldru",m II IlIr Ie. The U..., joinlllt \hr IC .. or 1M I'Ure UIf'U1 (500 nli"" ... <1 I'u ........ ""i.;n;. (11 
"liml). IIII.' , ... ""Ie ....... f~...,..tI Ib t .<ld;I" '" dT ..... OOlUIII Jloinu ab • ..-" Iht HIM' "'DOIt ~nb,~, .... The 
IC .. "Alue. In h~~tI 11111 ... 0 r..,,,,rimrnIJ urri,d Old in duplicale. 
Slimlar 10 Ihe inlcl'lellOn observed I'.- ilh the 01 0 ~raln of p , /uicipWllm. figure 4 2 2 shows 
dalum jXlI lltS Ihal lie above the lSObolc. suggestlOg an antago m,o;uc rclallonshlp between Ihe 
extract and art emlSlnln ~gu.inst Ihe K I main Oala pomls for combt.1I8ti OI1 mllOS of 12 5, 8 1. 
4 I show a hlllh I"vel of anfagonism Ihan Ihnt of Ihc 376 combi nallo n ralio suggesting I 
reduction In InlagornSlll Wllh Increasmg proportIOn of ACW I In Ihe combmatlon 
h blc ~, l.~. " .. tll'l~'II'Od'~1 :orlh" ly of AI'W I i ll <ombill~l ;on ... ,111 ~hl"rII' I~;". K~:oj "'IIII< o w .Ir~in of 
P j lllc'P"'M_ 
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The IC .. ,.,.1_ IU" baocd on I"" ""1"'""""'" canicd OUI ," dupllCIlC .... mrllbrd error o(.he _ cU;W3ia1 
at 95% cn"fldl; ,1CC ,oten .. 1 
The Q)nctnlfllilon of ACWI . 1 Ilk Ie", of combt1lOllJon _galllS! lhe ch/oroqulllc·sensllive 010 
strain decreases with Increasmg proponlOn of d1loroqulfIC in Ihe rombuuoon as snown III 
table" .2 4. GeometJieal InalySis of the 1e!luonshlp betwCCtl ACWI and d1loroqUllle Ig;uru;t 
the 010 :IINUn of P Ill/e/purllm show. I predommarul)' . ddll ivc rdallOnstllp for most of the 
combmalloll raliOS Inve;mgaled as shown In filture" .2 3 
,so 
• 
. -
-1 t -j~ 
'" ," 
• ! 
b 
., ~ 
" il • I . 
" o+---~--__ --~--~ 
o SOC 1000 1500 2000 
c~ .... . ~"'." ... uf ACW I "I <"", to ."",," Ie .. (D~ln, l) 
.1t ~ . 1.J. bl)~J"lIm 011"" ;nlo';>(II"n ""I .. ~n "CWI on" r hlll,ooIU'''' M~al"'l Ihr DIU ilr~ln or P. 
{./Cip"""'" 01 IIr Ie ... Thr Ii .... j .... nin; 1110 Ie .. Dllhe I"''''' e_" .. ...,1 (15 10 nt/nd ) ~lId pu .... tli lurtlllulnr 
{t 02 nz!mlj, thr i..w.le. ""p ...... "". I" addili,'e dTc-<I. [)~IUU' ,HiI .. " [ 10"" to \"" b"INJ.Ie "."',Ie an addlth. 
mal;"'n ... i ... TIlt Ie.. ..... UO$~ .... b;ur<l "" IWO .'''''''"",n" .... rIrtl aul1n dupllul •. 
' ·"bk ~.U A.nlp • ......,., •• ' arl;,·It, 0( ACWI I" fDIII";utUt .. 'ill! [hlon.qui"" .~ru:1 ,"" " t " ... in "r " 
Ilddl''''''''' 
C ... nhiIlUl ion nil'" 
( \C\\ "cht"r("I"'"~ ) 
>76 
125 
8J 
4> 
\f \\ I ;11 I( -... .. r 
... ",1"":,1,,,,, ( "~ ",I) 
2200 0 l' 25" S 
175R5± 127 
!2M 0 ±12H 
661 O:t1W 0 
(:ollrt"tnli" " "r 
chlurtHluiut ~I I(' .. or 
,-,,,,, h.n~I'n" ! Il l!. ",II 
1"21 1 111 
1520 :1.157 
1600:1:196 
n>e Ie .. ,-..1""" a.e b..saI on '"'0 expo"" .... " <;Ion'" 11.11 III d~llCIte and w!ld.-vd 0"'0< of lhe rraa c:alcablal 
:a 9-S"'. eOJlIid(11CC 10IIC0'.'ai 
The CUUccll trm Iun of ,\ C\\ I at the Ie 10 of Ihe comillnanon, agAInst the chJoroqullli'.rc~iSl~1l1 
K 1 Slram, II1clcases wnh the proponioll of chloroqwnc as s/!O""'T! In t~blc" 2 5 
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J~lcip;l",,,, ~I Ibr IC.. Th" lint jolini/> = .IM: Ic.., III , .... r~ rc . \l ratl (560 01:1 .... ) u d I'" .... (Ilia"",";"" (JJ~ 
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Unllk~ the relationship observed between ACW I alld chloroquine againsl the chloroquuine-
SC11$1UVe DJO stram of P jfllcipon"". dllum points in Figure 4:1 4 tie abo\'t Ihe lsobolt 
suggeStloll a strong antagolUslIc relauonsJup between AC W I and chloroquine ag.al1\Sl Ihe 
~hloroquine-resl s' nnl KJ Slnun The level of IlIllKIlOlUsm IIlcrease5 wilh Ihe proportIon or 
/\ C W I In the combmatloll In order 10 !RVesugale [he mcchuusm he/nnd this IlIIeractJon, tIus 
l,roJl"C1 !I1\,cslillated the "fretiS of IhlS exII1I.CI on the uPlakc of dihydroartenuSlllIll. the actl"C 
mtlabolJle oflhe arten1l51nin dt'11vauves 
" .J l::ffct:1 uf pla lll isola Ie 011 :lccumubtion of l l-I _DI-IA by erythrocytes 
The worling dose: rlIuge was selected on the basis of two clinical studies wllh the aim of 
makmg the SIUdy results clinically rele\lHll1. One of the studies was done among children. and 
reported a pafl1Si te clearance of 97-100% after 24 hours of treatment wnh mesunare I n thiS 
sll.Idy Ihe mean maximum blood concentration (C .... ) of DHA wu 018 flg/ml ( /I a/puap er III. 
1998). thl$ is equlval~nl 10 an exposure of 2 61 x 10" fmoll per erythrocyte. assuming a 
haemalocnt of 50'\". Hnd Ihal 11-11 of packed normal cryrhrocyll:s conlum5 5"2 )( 10' cells (Diem 
and Lell!ncr. 1970) The olhCl'" slI.Idy done by Na Bangchang N III. (1994). found stcady Stale 
concenlrMIOU$ of DHA I1II1SUlS from 36 10 60 n,!llml In the rher.'lpartlC U$(' of .nestllllre: this 
would II .... '(Juld mean lluil each crvthrocytc was t'Xposed to S JlI 10'\ to 9 11 10'\ fmols under 
steady 510re condition! Punmg mlO CQIlSIlienlUan the l'ffea ofproteUl and cellular bmdlll8 on 
In 1m, drug a"Rilabllity 10 erythrocyte! rhe aCIUIII drug e.>;postIrc is mUl:h ICS$ than camputm 
ab<l\'e In thl~ Study we used I dose range 0(068-683 11 10" fnlolslervrhrotyle belo" the 
cnlculatcd c.>:posure In the above $Iutlies 
.1,3. 1 Spe~jfic II cli"jry af J II - I)IIA 
A lillcar rcl~UOn5hlp between the concentrltian Rod disl!llegrauon$ pi:f" Ilimute (01'\1) was 
!Wumed III all the ~penment5 The 0I1.!!1II41 drug stock WII$ dllutetito a 7 1 4nm soluuClI! and 
from thiS 10~1 was used to delermmc the specllie lell"lIy The dlsHl1cgr.tions per Imnllte 
frOn1threc samples \\Jlh 714 fmols of1H_OH.\ arc shown In L!lblc 4 ) I 
Toht~ ~.J,t , 'h . ",,;' .I } '" r, .. hul.bdd tlih}" ..... nc .... tnl. 
i::l l'crimen l Ihug "1II(lUlit Oisinugrllliou$ lM'r Aft;' it) 
t rmal~) IlIinu"~ ( 1)I'I\I/r,"ol) 
. 
714 229n-a nl7 S 
2 714 2294642 32137 
3 714 2274673 ) 18S 8 
The mean aCII\11)' wu nos 7 '" 19.6 DP\I per fmole ThiS was used to delermmc the nmount 
of 'H-DHA taken up by erythrocytes aller an Incubauon penod thIS slUdy focused on Ihe 
amount of ' H-DHA e,,,poscd to each nyrhrocy1e and I'oh:\t percenlll8c of t1 is laken Lip by the 
infected alld unlllfecled Cf}1hrocyre Imponant assuntpllOns were mnde 10 achieve thIS, th~1 
Ihe drug bound 10 aJbunun and lhe WIllis orlhc Vl31s is ava\lable 10 lite eryl hrocylC~ The study 
used a haemalocnl of 1°'. Implymg lhal Cllch ml of ef)'lhrocyre suspenSion h~d 10 fll of 
CI1,hrOC)lcs The dose of1-l·DHA used in the ~lUdy 3nd lhe corresponding amOUllt ofdru!! 
c::<posed 10 eaclt el},hmcyte IS shown Illlable <1 J 2 
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The amount of drug associated with unmftcted erythr()l;)1CS at the dlnerem doses ID table 
... j J. wa! used to calculale the proportiOIl of the drug IlSSOCI~ted with the Illftcted 
erythrocytes. putting InIO cons,derallon the pal1lSnaellllB o f S-·. used ill the study The OPM 
due to 9 S~I of the umnfected erythrOC}1CS "'iliS deternuned IfI each set of e>cpenment and 
dedUCled from lhe recorded count 
'hhlc ~ .JA. The uplake or OIlA bJ ~Qlbro<")I'" Inf'CI~d b} III~ OIll,lni" "r P./",cq..,,,,,,,, 
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Ff}'hroC)'tCS infected With the chloroqume-senSlllve 01 0 stnun of 1'_!"lcl!X,flml look lip 10 & 
10 ~S J.,. of the drug exposed 10 each erythrocyte Increasmg the external drug concentration 
redute$ the percenlPge or OIIA Ial.en up by the el)'lhrOC}1eJ T~ trend IS ~hown In table 
"J 4 A 51nular trend "as observed w1lh the chloroqUine-and sulfonamide-reSiStAnt KI Stram 
of r J"Jclll(tnllll In table 4 J 5 The K I stram hov.ever took in a higher ploportlOn of Ihe 
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Table 4)6 shows Ihe effca ofCluemal drug COllCelllralJon on Ihe amoulll Ofl ll_DHA taken 
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(!!1It\defta lnlCr\<!I 
llle Iccumul.uon of 'H-DIIA In both I~ mfecled and unmfected tr)'hrC:I(:W~1 IJ It'.IIl{ICnturc 
dependent An Il'ICmlX of lempemure Irom .f'C to l7 . C HlCreasel the UJ>lUC uf '11-DiIA by 
ullmf«led CI),htOC)'C3lwD fold ",hlle the uplRkc by Infected IT)'lhrocyh:S', IrlCruJed atlellSI 
lIe\eIl (old 
A dOle o f 106 ~ tmoIslml wu u-.-d in 'tll~ ",lIIiy III bo: al>lc 10 dt:ltoet IIny rise Of reduction in 
amoune "f \"·D~IA ,aJ,;en up by III<! tf)11w0C)'~ Tbe mcumhon time of 2 tvs Will used to 
aUo", IS much lime as ponibte fL)l 'ht eqwhbnum 10 be established The elIpetlmem WlIJ 
tarned out I' J7 "c The ~I\ DPM (Of the unlllfcclI:d 0')1hrOC)Ie5 e:\posed 10 106 S 
remlomoltslmJ for 2 hrs wu ISlO l 11111<ou used 10 lhe calcullllOo of lhe UtJll!k1' of lU_DHA 
by IlIfeCICd ~rythrocylCS Th" pel\:Cfll8l1e uptu.e was WOI'Loo OUI IS do ne befOle The planl 
Isolale ,\CW I Slgmficanlly IIK'IeUcslhe uplale of'I I-DIIA by crylhroc)1CS II1re~led "ulllhc 
DIO S(nlll1 of J' ftlfc/pamlll al the oonccntl1lUons or ISO, JSO and 600 rl&lml (Mllnn-WhM'c), 
U-lcSl II < 005) These rnullS lJe sIlo .... n In figulc "J 2 The ~IllC doseJ of \ C \\ I 
"tlndlelnlly reduced lhe uptlL .. or 'H-DHA III crythrl'lC)1C5 infI!Cled Wllh I~ ebIol"OqunlC-
.1Id $llJphonanlnJc-":51.~ K I .11IIIl or /, fok/ptrum ii' $hown In ligUle 4 J J 
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4.4 Dism ssiun 
U&andan communities usc lntiillonaJ mt:diclllcs lS sdf-medlcluon, for malana ~ of 
these people end up 11\ health Unlt5 where antimalarial drugs are prescnbed rhll results mID 
coocurn:nl usc of tradi!lonal medlcmes and antimalari al dOl!!5 This study Investigated 
pOirnhai In!eflcnons bellleen ,r$l,lIonal lTIL'tIiclOes and twO Inllmnlarial dnlgll chloroqUine 
and &nOTlJSlIlIn An lsolue from A , ajr/cul/II, ,\C\\ I, IllIh alluplssmodlal aclmty was 
preferred to Ihe crude exlllCI 10 reduce the POSSibility o(exlra-cellular 1"1CrnClions 11lt first 
part of the study II\va;hg;ucd the Bllupllsmod,aJ le!lvlly of eXlraCT-dn.!! combination, agal Jt51 
the ~h1oroqtUnC-seruilll''e DIO, aod the chloroqUIne-and SlJlphonanlide-rcslslanl K 1 smull'; of 
p, ju/uplmlm 'IlIl' s«ond pari ch.araclc"scd the accumulluon or dlnydroarlcm'smlll (0111\) 
by P ftJClparllln Infected erythrocyte\! , and how .t IS atTected b)' AC\' I, The posSlb.IItv of 
competillon \)et"een the .solale and OIIA II ct'lIutll' lelel WIS born OUt of tile fact that A 
"iric(U/IJ belongs to the SlIme family IS Mnlllsil l lllllllft L. ASill"I<'/'fH! A lII/IJ,1fI l IS the 
source of the an\IInaianai 5Csqueterpent loctQf1e, anel1llSlnln whose defl\'1uI't'S arc """ 
wldel), used in the treatment of chloloqUIIM:-r~ISllnt m;llanl (Klaymlll, 1985, Hien et 0/ , 
I99J) 
This sll1dy showed that ACW I antaHol1lsed anemislnm It Ihe Ie'll In combl1\auon ratiOS 
(AC\\ t l111e1\1I511\11\) nUIsmg flom 4 to 17 6 and dose range of 1100 to 9400n!!lml fOl'" 
ACW!. and 250 10 7S0ngfml for arlemiSlmn This rclattonshlp was obM'r.ed "'1111 boIh the 
chloroqume-sensillvc DI D, Ind the chloroquine-and sulphonamide- reSIstant lei stf1lln of P 
jak"lxlfIlIIl, ",hlch is more susccpuble 10 both drugs Wlule blood concentlllllOltS of the aclile 
principles attained during thClupeuhc use of tradItional IlIc<liciJlc.$ lie not known. COmb11lilllOn 
slUdics that used startmg concentrations a few llIultiples the Ie'll Mve produecd dmlCally 
n,levant findmgs. 
A combtnalion of ACW I Dnd chloroqumc produced ~;mllir results a~m5t the chloroqume-
reSIstant KI Slram The colT\bml1lion ho\\el'c, exhibited nJl addn!l'~ rcl:!llon.~hIJl agal1lSi the 
chioroqullle-scnsuive DI D strain of P ft"~II}{II·WII 'rileS!: nndmg.5 suggt'sl lhal c."tracts from 
A. ajrlc(UKI could ant_s0lll.'le the IJlIUTwanal eflh:t of chroloqumO! or Drtt'I11IMllU1 when uS<)d 
coocunently 
79 
The ImcriICUOI1 observed dunng IsolBtMl'\Jg cOlllblrulllon siudies could occur extra-cellular. 
at the er.lhrocyte IIlo!mbrant, In dl'\Jg transport pBlh", .. ys or at th~ IIltmceliular drug larget An 
e>:.tra-<:ellular mteractlon wlluld lIenendly 1lIIIOIve the fonnaiion of an extract-droll culllph:.'L 
Tlus pheoomenon has not been wtddy dlJeuSM'd In reference 10 11/ 1'1'1/"0 dl'\J !& comblnallo n 
sludles. yet It could explain SOllie of the observed Interactions The ..,rreel ofthc plant Cl[HICt 
on the uplake of dihydroanemisinin by P jaif'/l"flil/J infected erythrocytes provided 1lI0rc 
evidence Oil the poSSIble Site o f Interaction 
In Ih'5 S1udy, we observed 111m erythrocytes mfecll-d wllh the 010 Rnd K I SlrlillS of /' 
{lIlclfX/TilI/l actumulated dihydroaretllli smin more than uninii.~ted erythrocytes Similar 
findings were observed by Gu el (1/, 1984, Dnd \feshlllck 1'1 01 , 1991 Hwcstlgated lhe 
mechalllsrns bellilld Ihese observallort$ " he upuke of JII_DI IA \YoU round to be dose 
dependant . Sil turable and temperature dcpcndam. findings HI agreement With the " 'or!.; of Gil 
1'1 (d , 198<1 and Kalllchonwongl'llSiio rI a/" 1994 
Pn:vlous studies. suggested that anenusmln and ItS denvatives are transported through the 
tuhole5lcufar flCtwork tcxtendiog from the l'arasnOf0ll5 vlICuolar membrane: to thc f'Ctlphcl)' 
o f the red cell) wllh hell' of 10 energy depelldent carner protem (Akompong j'f aI, 1999, 
Nehftl d aI, 2(02) The probable target arcas fOr these drugs are Ihe parasite ml'mbrancs, the 
I'arasi lc food vlcuole and hemozom (EII.s er (II 198~) These drugs ue also dist ri IMJted 
cxtenSl\'cly 111'10 the cytosohc coml'anmeTil and Crythroo;)11C cell membranes (\'allanav,boon 
cl trl. 1998) The ultimate C)10to~1C eRect of artemlSilun and liS IknValll'e5 has been 
atlnbutl.'d to the Ol[lda\1on or cellulu membranes. and denatura llon of parasl!e protCIIIS by 
o,)'gen-llnled fie< radicals thaT lIe generaled at tile clcavage o f the peroXide nng (Hong 1'1 
(11 . 1994) 
TIle: plant .5(lII !e ,\ CWI . reduced the amount of l ll · DIIA taken ul' by KI infected 
Cf)1hrocytes On the other hand the Isolate enhmced the up take of ' H-DIIA by 010 infected 
erythrocytes In both Clse), Intlg()m~m had b.:en obserH-d (!l the combination studies We 
had also obsc"e(f earher That the KI Slnlln ftcCUm ul Uled ' II_DHA morc ellicicmly than the 
010 stram These lirullll!!-'i sugysl that the mechanism of aCCUmulation of DIIA Into 
el)'lhrOC)1eS lIuecled \~,th the chloroqulllc-sensUlVe 01 0 stlll in IS d,lTerent fiom that o f 
Cr)1hrOCyte5 InfecTcd WI' h the chloroquill('. alld SldphollftliUde-rcslstan t K f Sirain Thc K I 
5tralll seems \0 hal'e an I1 pL ake m~'Charusm that IS more cfliclcl1! and IS Icadlly blocked by 
so 
ACWI. D rneehanl,m thal may be lacking III tk chioroqlllne-scnslt!vc 0 10 strnln of P 
fukl/1(JrJ/1/I Other researchers In our laburnlOry have also obscrved difference.!: In 
IICwmulauon ofpyronandlne between the 010 Dnd K I st rain 
The 11/ "/fro 3.ntagorusm bct ..... l:Cn I\O\'I and lIrlemllinin llgal1l5t tile 01 0 ~tm lll of P. 
fil/cl/>cmu" IS RSSOClDled .. mh Increased acrumulallon of lH_D IIA by lilt erythroq1cJ TillS 
""ggesls a poSSIble InHacelkJlar IleUlral!.loauon of lhe CytOIOXlt free radicals, "tneralcd by Ihe 
de'dvage of the peroxKie bond a5 a poSSible eau$(' of tile Qllla"OOlsOi II has already been 
postulaled thaI .:;ompounds WIth antrO~ldant properlles could DlllagOntSc the al1l1malar ml 
atu .. ,ty of anemlsmm and liS den"lItr~s by nnrtnilisUl.!l lhe ftec radlCills tllat are rC!Jpon5lble 
for pafUltt dCalh (KrungJ.:nu and Yutl!it.'ong, 19117, Meshnlek 1'1 (II , 1989) TIIC5e findm"s 
IOgether, sug&est that the A UjrlaMllJ lsolDle acts inlJ'llcellarly 
Tht plant CXlract Iw:I an addiu.'t' Ind amagomsue relallonslup \\nll ehlorOlluUlf;! againsl th~ 
ehlol"OlIUmc-senSIII\'t' 010 51l'1ln and the c hiOloqume-r~stant K I Slram respectively The 
mechamslll of tcSlstanct' 10 chloroqUine 15 not clearly estabhshed, chloroqUine reSl51DIl(:C IJ 
I1owe.~r associated wnllreduccd accumul~hon of chlolGqullle into tile parasne food \lI(:uole, 
The cffCl:t or the plant c~liacl on the uptake of ehlolGquJ1le was no t 51udled, SlOtC the Isolate 
antagonises the dli'1:t of chloroqUIne In Ih~ rntSlrmt 511am aod not the scns,t,,'c I1ram, we 
postulate Ihal It accentUDlt.$ lilt chloroqUine rC:Sl5tMnce mt'C hanlJms, reduces the aetumulallon 
uf chloroqume m ,he pllB!Il te food "l\Cuole 
It 15 generally dIfficult 10 rephcalc tht III ,'"VI dynaml~ m In m \VIm syliem. to SIUdy drug 
lUlel1lctlon5 /11 ,'"m .ystem! lack prote1ll and cellular binding, m('(aboJosm, and l'llmllliluon 
To Iry and Knam chlllcal relc'lIncy, thiS sludy U!lt."d duStS or ' II-DHA lhal arC" close to tho$C 
al1umed 11/ \'1m under therapeutic coodHlon~ The blood !e.'e!s of lICIt"C pmIClpk:$ aUDmed 
dUllng the! tradilional use of A IIfriClllwl are 1101 known malqng 1\ dIfficult to worl. wllh 
ebmcally rell'vant dose ThiS siudy only bnnp OUI Ihl.' pl!cllOn"K'OOIl. .... hlt h can be 
investlglucd III dUll(al studies There 15 need ror studies to " tabhsh the effect of tIns 
ph~nonrenon on trealment outcome in malamt patients IlSlng c,~tI1leIS f.om A ili""l"", 
loget her Wllh anllmalannl drul;s 
·1. 5 Conclusion 
The plant Isolate ACW I from A (iff/C(II"I, a plam traditionally used m the lIeatmem of 
malalna m east aoo cemllil Afncn antagonl~es the anHmalansl aetJVlt~ of chloroqume lind 
anenusm," al some combmaHon ratios agai nst the chloroqume.sens,u\le 0 10 and the 
chlorOQUIne-and S1lIphonamlde·re.,stant K I StrUlIIS of I' /u/cIIJelrlllll For arte!1l1SIIlIn, the 
possible mechamsm of antnl!Onlsm 1$ the IIIlubltlon or drug Qccllmuiauon b)' mfected 
erythroc~1es or neulralisatlon of the mtmccll1llar cytOtoxIC free radicals The Isolate probably 
accentuates Ihe reliistance mechulIIsms in chloroqume·resisln ll1 Sirams nll ~ sllJdy bnngs OUI 
tile ~rd \0 establish the extent to "llIch II1Is phenomenon conlllbutes to treatment failure 
IImong pallcms taking tflld,honal mcdicllles t0l!elh~r wllh cl1lorollulnt nnd artemislnm ThiS 
calls fOl'" mcreased ,n'ellllgahon mto Interactions between drugs af\d traditional medicines and 
the need 10 lake caullnn wlt,le prescnb'llg drugs 10 llauents who nre t"klll!; tradillonal 
med,cmes e,'ell "hen they are used 10 Ileal the SlInte cond;lton 
CIIAPTEH 5 
The ''.!fel'l of eXlrllelS from Gm!ifJ.\perwllm Iw/iC(lCflblllll (III/I 
MOlI/orr/iclI foe/if/II (II / dis/!Wil! progr/!ss ill II IIII/rille IIImll!! of ('crl!bffll 
11111/ fI ri II 
5. 1 IntroductIOn 
lbe IWO plants Mumon:ltcapllr/<I Scbmncb Et Thonn and rardiosl'Crmll1ll lIaht'lImb"", are 
tlunben tha t grow WIld In foreslS of East , Ce:ntml lll1d Southern Africa. Leaf decocTions from 
tbese pbl\l$ are u~ In tbe: Irearrnem of malana rdared symptoms ill addi tion to Other 
aliments (11:J.kwmungu t l (II. 1992. Rwangabo, 1993) Extracts from aenal ShOOls of thes.: 
pl.lll15 did not 5bO\1/ Slgmficant anuplasmodlal aC\l1/lly Bg:tInst tbe cbloroqume-scnslIl\'e 0 I 0 
4nd lhe: chloroquine- and 5lIIphon.:unide·rrslSlIlll! K 1 stralns of P /ulo"",I1'" In the firs! part 
of IbiS study. reported In chaplet tbret: 
In IllIs ehailler we: r<!pOrt the efiocl of waleI' e:<:lraCIS from Ihe two plarllS on the: development 
of murme cerdJrul Ilullnroa Th" STudy was limned ro warer extracts on tile basis of 
cthnopmCllcll$ rcporwd by tmdllional haler$, 111d clhnobolllnical 5I.W·"eyS 11H: waler extracts 
\.Icre obtamed 11.5 reported earher for Ihe 11/ '"11m siudies The extTllC\5 \.I~'Ie dl55OIvo:ll in 
phoSjlhatc bun"cred sali i\c solulron (PBS) In prepMalioo for adnuruSlrnlioll A munne model 
of cercbml n1~llIna was sel up 10 detcrnulle Ihe rullUf1l1 !uSlOI)' of Ihe dlscase. I IlII:rvenllon 11\10 
the dlSellSe course 'YIU by ornl atlmllllSlmtlon of water extracts The CS7BL micc and Tlte /' 
br-,¥h'.'1 (Anka) Slmln o f rodent malan a were used 111 litIS sludy The !luce were IIlrect~'(/ by 
intrapenlollCal adl11ll11strallon of Ild07 inl"ecied crytl!roc)'!es The parnSlIlttlmlt, weight 
changes, suNIVl1l lime and hacmnlologlcal parame1el5 lYere studIed anti used 10 rnonitor 
disease progress Oe\.llils of materials and methods used are described in chapt ~r IIYO 
S.2 T h e " :ullntl h is tory of P. herg lrei (Anka ) IIIl1lnri:t ill the C 5711L mice 
l"able S 2 1 sllows tbe developmi'fll of parasilacrrua, and the survIVal or CS7BL lnice mrected 
With I' berg/wi (A llx,,) Dealh was firg obscncd on tbe SI'(th day post·mfcchon and all the 
rnfIX:ted IInul1:l1s tlletl by the I.'Ig.IlIh day post·mfwIOn. Dalh was U5OCl3 ted WIth 
con1/UISions. rnpld brc;uhmg and high pansnaemaa. 
----------------------------------------- '3 
Oa) 5 pOSi-inrttlil'n t\'fI"~g"'lmn3it :It'nl i : 1 ~I ortalily (P~l\"tn l agl'~ 
f PtITt'''IIj:o:') 
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'_ F W'M 0 0 0 
2 0.3)±06S 0 
, ~))± I 53 0 
6 25,0:1:.34 60 (6110) 
, 3)7l:S I 100(10/10) 
Values ~tc basal "" .hm: 1l,da pftp.1fN from one Rn.!n.,1 lhe sland,,,'ll errol ot' I he me:"11 was cOlli PUled a. \l5~. 
COllrKlc.1CC II>lefY.ll 1'erce"1~~ mon~!ch ":IS clcIC""lncd br obserVIng I II ""a: 
ParlU.taemm was eo.'.dent on the JCCond day aOer mfoction, the highest paraslloemia li llalned 
.... :u 14~. Oil da,' aght 
II ~ t,"ogl ol, i" II:1tClll'!;luhin ~OOtt" l ralion 
011 ) II(»)C" Ur«l lvll t UllrtllCr;I.iun of or ill rttl .. u mitt UI.",I<lI) 
""111rt(l~d ""~t gm/dl 
0 14 7 
'" , 132 14 2 
, 
"' 
117 
6 ND ,0< 
7 ND 
" , 147 70 
There was II progrC'S$I\'C reducteon III lucmoglobm concentration dUllng the course of 
infectIOn The Irends are sho"TI 111 tDble S 2 2 The lowes! haemoglobin concentratIon 
recorded WIU 6 5 "midi on day seven The haemoglobm conCe!1tranOfl did IIOt !iIIow any 
SjgrunClllu changes In umnfocted IIllce 
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The total leukocyte count mcreased through lhe: urne of mfectlon The h.ghest loull count 
recorded was 17 7 x 10' n lIS shown m table S 2 J Leukocyte d.iferenillII counts showed 
prugre.ssJ\.e reduction m the proportion of Iymph0C)1CS and I rise m Ihe PfopOlllon or 
monocytes and nutlroplub during Ihe course or Infection. The lotal platrlet COOni reduced 
dunng Ihe COU' 5e ormunne malaria mrcclion as shown.n table S 2.4 
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Figure S 2 I shoW5 that the mean group weight of nllee increa,ed nonn~Uy In Ihe first four 
days of lI1(ecUOIl, whlcll WIIS followed by a steady weight redueuon up to Ihe dermse of Ihe 
study arumals The unll1fected "roup of ~ninlll i s had Ii\(~ildy i llcr~ase In weIght 
-: 
~4_ Uniufec lNI mi ce 
17.S 
...... - Inffclfd mict' 
151)+--~_-~--~--_-~ 
U2~b~1<I 
Days of""st-;n"rl;on_ 
Fi:! S.Z. t W.j~ht d",,, g~. ill P.b''I"g''ci ~t\ "k~) j"r""t"d C571H. n';e .... V" I"", ~r~ hu",t UOI 111 "nimal.' ~ t 
cn""n~"".n,.nt "r "-'I",ri ment . The '1~ "d~roJ ~rt1Jr "r Iho 1I"·.n '"'' ulcul"l~d ,0\ '15"/0 eqnfld."cc 
I"," ..... L 
The findings on this m~lnria model show a disease course al<lu 10 human cerebral malJria. 
whose symptOms have ah-e3dy been descrtbed in the ftrst chapter One differente. however. tS 
Ihe high differenttal Increase III the number of monoc)tes dunng the COur5~ of infecllon This 
model was used II) siudy the efTect of water extmclS of AI fO<:lIda and C. /",/icamhfllll on 
dise~s~ progress 
5.3 Pr'climinary tcst on w:ltcr c,~tnlcts uf M. liJelidll aud C. Iwlic(fc(fblllll 
f'teltmmary screening was cani~d out by administering 250 mg/kg of Ih~ water e.~lracts.. by 
!:Ia5lftC lavage, tWice a duy for lour consecuttve days to I' ""rgll<'1 (Anka) mfccled C57BL 
mtce The study ammals were monitored for parasitacmia, wetghl change aud monality A 
positive control expcnment was set up In whtch the micc were gtven chloroQume (1 0 m!;lkg) 
tWICC a day by gastric lavage The shldy parameters wcre compared wnh lhose observed m 
untreated animnls 
The nllCC thai received Ihe e.XlmCI of oil JOi!lIdil Itved up 10 Ihe 13th day after mfecllon. 
beyond the maximum S\lrvival tunc ohserved with the untreated alllmals ParaSItes were 
deteclable til hl00d Oil day eight of mfectiDn. The animals however. showed weight loss much 
more Ihan the untrealed mtce (ligUle 5) I) All the mtce treated with the water extract orC" 
--------------------------------------------" 
11{j"~HI.·tlh!lm died In IirSI four da}s of Infection and tr eatment. The mICe treated wnh 
chlDlOoqullle had no evidence of malaria for lhe 13 day' of experimental ob$elVluolI, un Ihe 
olher hand they sho .... ed normal "'eight gam throughout II\(- study penod. a, MtOI.lTl In figure 
TolIl. ~.J.I Su";,,,,1 "mt " ar;<';I~c"'i~ .... t"~ d~"tb day ~flu I""tmcnl h' P. ."1:".-1 (Ao h ) infrel. d 
C~71ll micf .. ilh or,1 rhlnl· ... \u; n. (21lm~~"~' ), .. -al~r n U-,el, f>I M.J.",ti" (~ .. dtjt Ida)) ami C. 
hulic"""h~m [~ ",~=,da~ ) In I" 'n di"idnl 01""", for ~ u n .... "';, . "'lH' arlin~ on Ibe d~, '" inf« d •• n. 
Druw PlllUI fcn-tnlage 
e,.,Ir":lrl su""i llal 
, , ,-
ChlDloqumc 10(l 
"I i".:IIr/{/ 100 
C 'klIIfW(,'(/"1I11l NA 
UOl/eated II\Ice 20 
Panl5il:ulllili 0 11 
d~)' 8-,1O~1 
infection . 
0 
2 
NA 
, .1 
P .. rtcnUgr 
IJilr.\silar.Ulla illbihllioll 
100 
94 1 
NA 
NA 
Vaklrl a .. b.:ued on ("'e >lUll> ~"",,,,b ,II Ibe .. """,,,,na:,,,,,,,1 of "\I"'"m;:nl NI A InOi appl,Q/:Ile) ,'''''', puups 
"I",,,, 111111", BR"..,lJ h.od dlCd 
Analysis of some of the siudy paramelers 011 day cillht sho\V~ that the wate, elCtrael o f /II 
fill'llda WliS well tolerllted and had a 94 I percent I11hlb,t'OIi at ~ do,c of ~oo mglkgfday 
adlTUmstered In two divided dOJe) as shown on table 5] I The pos't lve control, chlo roqUine. 
10 a dose of 20mglkglday in tWO divided doliC$, complctely protected CnBL nnce from 
deVi:lOJling parBsulICfIlla up to day eight of mfecuon The mice thlll were treated With the 
water extract o f C. htlftcocahlllll died by the fourl h day of mfecllon One of the 1 u , BIHnlals 10 
d,e In this group IuId a paras ,taenuB o f 4 4~· •. close to the observed panul taenu3 of ~ 3]% UI 
umrc:ned arumals MoS! dei>lh occufTed w,th In 12 hours of adnumSlermg the e~trhCI For 
both e\"tfllcts Ihe m~e gener.!lly los' Wctght IS show'n In Ilgure S ] I The ml~ treated WIth 
ddoroqurne gamed Weight steadily and d,d nO\ develop paruslIlICmlli 
--------------------------------------------'7 
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'''I ' 
.1;: S. J. I Wej~hl ~h.n~"-, in P. /H'f'gh~; t,\ nh) inr":'~,1 Cllf11. mIn ~urin~ nUIMtftI .. ·j.h IInll 
d,k1 rn'I";"" ~O"'::I~::I~ ~". "-"~r C~ '''~''b of M./Ik'I/"" ~llntfk=,1l:a1 . nd C. Ir"{;""""b,,," ~mtI\C~"\O,l ill 
II ... , di. i<lcd do.c. for ~ «m_,,' i' ·~ d:.), "a ... i n ~ lin tho d~)' ''' Inr~.,,,,,,, n.. mull> ~rr .nm~arr" .. j,h 
'he \I< igh. d' " n ~ •• In ;n,.,'.d ~nd uninr.."." mice III .. ·hich "I""r min "err " "''' /11- 10. at 
mmmen.~m ~,,' 1II .'l'<'rl",." I ). 
5.-1 Efft'CI of ex t rae! dOSl' on disease IU'ogl-ess 
Tile water extr~cl o f At {flclllI" was !I1vesugHled funheT t(I deternune how dlffere!lI doses lie 
tolerated and the correspondmg anumalarlal nell'my The plellnlln3ry e~peflment had ~howll 
that the highest dose Ihal call be adnlln,Slcro:d in D volunte less 111811 02 mls w~s SOOmgl).:g 
due 10 solub.hl) CuMlrDJIlIS To be able 10 achieve a do~e of lOOOmglkgld~y, the extract IYU 
given In two divided doses 12 hours II part The de\'elopOlelll or parasilaemia. Olean surv ival 
lime hlld weight thanges were used 10 mUMOt disease pIOllre~, 
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J /~ - .. - 10 ml:/k~/dllY I -- 200mJ:lk::fd.y 0 )0 , ~ I - ·400 m;fk::/d~y 
" ! ~-.( , A - 1000, :/kl:/d~)' • " • ." , 
" / • I I ; 
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" A I I , I { " .A--.:-~ ,-1 , , 
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" 
lby, IMI$ I - i"r~c li on 
FlJ! ~~. I . 'no~ .... H .... "."'''' ur P.It~'1:~rl j'\nl.~ ) pa""'il~.mi~ in CS1l1L mioe wrjOlt I",a' '''~nl ... ',h rnur 
~u"". !8. ZUO. ~IMI;o/Id l ooemto Ll1d~! III , .... ".'or cUnK, 01 M.j""n. ti.n ill h"~ IIhidell II ....... ' (ur 4 
0......,"";,. d •• , ".";n~ .. j,h 'he ob! t.t inf«.ioon. VallKJ art b .... ., .... r .... ,· ,Iitkf; I"cporrd (rum ,W/> 
.,.,1,' ."in.al. ud Cnn'l'lI" ,I " '5% conlid,noe ;nlen'>!. 
A dose of 1000 mglkg!d_y of lhe watel ''(!T<let of M P'lIti" gi\'en in ' .... 0 dl'lded dNcs 
delayed the de~dopmcnl of parllSuaelma by 6 days The lowt:r doses of 200mg!\glda} and 
400ll1g1kglda~ al,;o delayed the development of I'Mry.:11i'1 (Anka) pa"Sluu~ml.fl m CS78L 
mice O~ shoWTI In t1gure 5 4 I All .\1I11C\ doses wl>cfe wen lolcra' eu by the study 1IIUmab 
TIle: mean survival lime of I'.ix"'f:/x', (Anka) IIlfected C57BL mice IlICrea:ied "'111 tncreasang 
duse o f e~traci IIdttunislcn::d The mice Illal /ecc t\'cd a dose: of 1000 mgl\.Wday had a meal! 
5ur\"l\'ul wtlc or 179(16 l-IQ 7) days wnh lIne ofthc UltCC tn the group so/wltng up to 20 
day~ 9S shown III lable 5 4 1 The mice did nOl show SignS of CCII:bral malQJla al death and 
Senclllily dIed WIth lowcr P"rl\Slt~cmlll th nn tile umrtllted mice 
T~bl,' 5.4.1 . Sun" ~L of P.Mrrfhn ( ... ",,~) inr""I N C~78t. .. ir .. d .. n_: I",~' ..... nl ,,'i\lI r .... ' II....,., ~Q. 211t. 
I r~t ~n,r IttOUm~III"~) nr 1110;: .. ·. ,u c" "..,1 .... Itt /_,J". TIlt Ulrul ....... ~1I.'i"i .. u.,1I ..... ~Ih in 1 .. -" 
11,,·,11,,11 d"' .... rllr 4 <lt n""<,,,i'·t Ibn '1~"l n"( "" Ibt d~} .... '. frel" .... 
, 
J 
, 
5 
o 
20 
200 
400 
1000 
70±040 
72±039 
I02± 2Q 
BI±I S 
179 ± I 8 
Values ~,. bn.ed on W m~ :II llle (OtI",,,,na:,,, .. ,K of ""p',"''''''111 Ten ""u wen; SI..d,<d til 1"0 '"t)''' I~t 
C.'""I1m(ttI' ~tllI IIIe ~lncb'd <I"" of 1M ........ alcuLoICd 31 95~ .. cnafllk ..... "I~ .... ':II 
Th~ nItal! group wtlghts of nm;e In.:r~ased 1I0l1TlBUy In tM fin! 2 daY' o f Ihe txptmntll! as 
5hO\\-1l In fillure S 4 2 T hIS findmg IS dlfferenl from v.hat was ob!iC'l"\~d In the prehmlll.llry 
swdy In which )'OUIIII 1TlIct' \'oere used and less lime for aedim;allsalion ",,'U ghen resulung 
,nto welghl reductio ll from the fi rst cia)' orthe e: .. penment The ,velghl Incrnse was follol'>ed 
by a s\e.1dy reduc!lon u the dIsease: progressed Antmals mal rece,\'td s!II.:tIUer doses orlhe 
eXlmct los! I!lo re weIght than those: treated with high~r exlrac! dose 
• -- 20 mgJkglday 
" 
--200 mgJkg/day 
_ . 400mg1kgJday 
- - 1000mg1kglday • 
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.·i~ SA.!.. Wti::"1 th"n~"' ill I '.bal:hl V\ nkaj l"r«I<<I C.~7UL. mice Iru,.,1 with r,~,r tlO)~" !O. 200, ~(ln 
"",I I!HI()nl~k~~.) ,,( the " :Iter e'lr~n ~ r M. p"",,'''' Th,· n(r~rl na •• dmi "islCrrd '" 1,.." di,·i dr tl ,I"",. 
ror four "",,,·culi .. d.). ~t :tI"ti" ~ IW' th da, of i"f"' lim,. V.lu., u e b ~,cd "" 10 ."im.l. al the 
C<lmn,."cc,"r nt of 110 . "'1 .. rimc"l. The . 1"nti" ,·<1 " rrll ' u( tht n, •• " .. ·05 comp"led .1 ~5'/O ~II"fidr.n'· . 
j"ten.1. 
rhl s sludy set O\J I 10 establish a Illunlli: m(ldd of ~er~bral malana thaI would then be used to 
tnvesllgat~ the anllnmlanal propenies nf e)<lracts rrom /II, fllt'lId" Schumch Et Thonn and C 
1N.lllc((/~r"lIl11 Infection of C57BL nuce ',tth I' berg/wi (Auka) resulted imo II malaria dtsease 
model w,th Ihe key stgns 01 htgh parasttaetllli, convulstons and reSp'fotury dtstress Olher 
dis.:ase signs obseJVed Included anaem'a. leuCOC)IlUsis. 10" plmekt count Ill1d weight loss 
These St!c\llS are Sttntl3f to Ihns~ observed in human ccr~bral mala!'!a (English c / ttl. , 19%) 
In the preltminary study. the water e'(lrac t of AI jr'l:lida "as well tolerated and delayed the 
devdopment ur I' berg/lei (An~a) mfecllun tn CS7BI- mlcc On the other hand. the water 
e.'I[tnlCl of C hahc;tI(;abulII L caused deallilO IlU Ibe study Ilmmals witb III the fil1it four ds~s 
of IIIfectlon, wnh no evIdence of prOlectton agamn I' bughel malaria No autopsy was done 
bill most of the study arumals died wnhlll 12 huurs of c:<tracl RdminiSlrat,on. raiSin!! a 
possebill1y of an anaph)lacuc reaction as Ihe po5slble cause of dealh The POSlllVC comrol. 
ch!oroquIlJe. offered absolute prolechon ofC57BJ. mice ',!Ialllst mUflne m~lunR 
On furlhes IIIveslIgauon, lhe four OOJes 20, 200. 400 and 1000 rnglkgldny of M feotida 011 
were "dl loIer:u"d SUf\'IVBI lime of mICe lrl(;reased ,,!th ",-"Iraci dOk TIM: ~x!raci did not 
how~, provide 101.11 protecllon II.S aU lhe !reated anllll.1ls evenlually d'l"<i It has b~en 
repofled llial tlus e:\:tT1lCI hIlS no slglUflCllnl III vllro antlPlasmodlalllClivlly The III l'il'O ",!feet 
could be due 10 mclabolic lICu~allon oflhe plant COll!illluerus. or the consttlUefllS req\llr~ lite 
Immul .... Jysl~m 50 lIS to h.Jve lUI efla:! The po$Slbihly ,hal ,he III !'lIN, assay could 1I0t delect 
the an!lIlIaI.ial acllVlly. for 5I:veral reasons may not be ruled out 11.1051 cl\emlcal cunS!Iluents 
of AI jucll(/" remam unknown. nlld II""r characten!ll110n would help pr~hct the 
pharmacological propenles of tiS e.\lrIk.U 'Tho! e'l[Ir&C1 suppreued the d"velopmem of I' 
ocrgh..; ('\nlll) parasl1aemll III the firsl days of InfeCtIOn, thiS suggests It lI(ts on the blood 
SIKges o f the maim! parasne The subsequent de\dopmerlt uf rnfectlon in aD the study 
ammals pumls to slion e>;lraa duTlllluu of aciran, probably due to raprd melabohsm or 
ehnllnallon 
The wuter ~lfllCl orr '",/u:a«lbum .... ;a l~ tolerated than that of ,\4 file/hili EthllobotamclIl 
foUlVeyS reponed the Uloe of a 12-lIour nlacerouon of the aenal pans of this plant bolh orlllly or 
fer balhlng In Ihe trealment of fevel (l\dJlIroolioun It/ <I'. 1(89) The U~ of \WO rOUles of 
adl1lmrsrrullon could arguably be funller e\'!dcoce of 10\iClty, m ..... hich case the or.JI rOUIe. 
which ruulu In 1»:l:I(.lly IS being ab:tndOl\ed III favour of the ufe 'OPICni roule E"tllCl metric 
do).(.""S of (h~s" planl e.>;lrDctS used m tradillon."li medICIne are IlO{ known, II IS pos..lble that 
pl;ul1 eXlrD~IS 1M low""r doses are safe. TIle jJO~blhty ,It~ mice died due 10 anaphylactIC 
shock I' worrying. aid flll'>d need for flanhcf m\"~5118~1I0ns Into lhe ImmunolOgIcal "neelS of 
e..~II·IICI S Iroll1 Ihls "Iant IlypersenSI\IVlty rcacuOIlS wilh herbs based on Iradltlonal medlCll"ICS 
are !lOt ullkno"n. they millie from nuld dermulI1I5 I() lUIaph)'lacuc reachons (Perham: t'/lll, 
19(3) 
T he mulnnn dlSCi'se l1lodc:i u$etl In Ihl$ slUdy Jacks Ihe msec! VttIOf, and lIuhscs laboratOl)' 
Inor.:ulOlion duses. lhese result 11110 mllid Infection of ~'!hrocyt" without gomg through the 
liver stages, generally higher paraSite loads arc achieved than dunng nalUral illfectlOn. This 
would reduce the effecllveness of test drugs under invesugation. Small mammals arc kllOwn 
to metabollse drugs faster and usc different metabolic pathways from hunlRns (Anonymous.. 
1984). this could result into reduced eflecti,·cness of the e.~tract under Investigation hi fnct 
small mammals reqll1re about fl~'e limes the amount of drug taken by humans to produce the 
same etJeC! (Freueich el al., 1966). The 1.1 jUl.'lidu extract could actu~!ly possess better 
anllmalarial activity in humans than obsc .... ·t'd in Ihe munne Inodel The different metabolic 
pathv,ays could also result into a thfferem tO~ICIlY profile III hllmans 
The munne cerebral malaria disease model has a strollg role of monocyte leucoeytcs 111 
disease pathogeneSIs compared to the human disease (Neill el al. [992. Sem '" al. 1993) 
These serve to block the cerebral microvasculatUl .... a role played by erythrocytes in human 
cerebral malaria It is not obvious how thiS dinerence 111 pathogenesis coul.1 affect treatmem 
OUlcome but II deservcs memlon. It IS also imponant to note that the plant M. jUel/rla IS Ilscd 
in malaria treatment III endemic areas. ami yet our model U1iliscd natve mice With no prc\lOllS 
e~posure to 1I\.1lan8. tillS could Rlso contnwte to IhC' level of e.~!ract antimalarial activity 
observed In this study It IS c.~pectcd that this extrnct has better antim.alaria[ acti\1 ty In humans 
who ha\e been exposed to malaTlB, than III an experimental system uSing 1I1lmunoiogically 
1\.1·I~"c anun.lls 
The pathogencsis of cerebral malaria i~ different from unoomplicated malaria It is pOSSlb[e 
that the e."(traCI could ha,'e shown daTerent results If tested In a model of uncomplicated 
malana The duration of mal,1fta treatmenl Wit h the leaf decoction frolll AI jll<'l1(/(1 in the 
Iradlt lonal treatment of 11);t)aria IS not defined In lhls expcrlnlCll( the e"(t mct was administered 
for four days. there is need to invesllgmc the outcome of this study If the e.~traCI was 
administered for longer periods 
5.(. Couclusion 
nll~ study ha~ shO"11 that oral adnllntstratlon oflhe water extract from it,,[ jl/dick! delays the 
developmcm of murine cerebml malarm This extract was well tolerated 111 mice up to 8 dose 
as lugh as [OOOmg/kglday The protection was not nbsolute oowC\"Cr. With tile expennlemal 
Effect of C. halicacahum and M. foetida on malaria disease progress 
animals dying after 3 weeks of infection. The water extract of C. halicacabum was found to 
be lethal to mice; animals died within ours of receiving the extract, from possibly 
anaphylactic reaction. While more studies are necessary to confirm the toxicity of C. 
halicacabum, extracts from this plant should be avoided. There is need for further studies on 
the water extract of M joetida, especially observational field studies to document its efficacy 
and safety in humans before it promoted for use as a herbal remedy in malaria treatment. 
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General discussion and conclusion 
6.1 Study background and objectives 
The antimalarial potential of Uganda's traditional medicinal plants has not been explored despite 
their widespread use by communities. There is no information on their efficacy, safety and 
interactions with other antimalarial medicines. New malaria remedies need to be developed as 
parasite drug resistance spreads to cover species other than P. Jalciparum and new geographical 
areas. The main objective of this study was to investigate the antimalarial potential of some of 
Uganda's traditional medicinal plants. To achieve this, six plants were selected based on the 
literature, ethnobotanical survey reports and the experience of three traditional healers practising 
in this country. Antimalarial potential was assessed with reference to efficacy and safety. Safety 
was looked at in the broader perspective to include negative interactions with other medicines. 
The study used in vitro and in vivo experimental systems that were set up specifically to: 
(I) determine any variations in yields and antiplasmodial activity from these plants; 
(2) investigate the antiplasmodial activity of extracts from the study plants and compare the 
activity on both chloroquine sensitive and resistant strains of P. Jalciparum; 
(3) determine the in vivo antimalarial activity of extracts from plants that did not show any in 
vitro antiplasmodial activity; and 
(4) investigate in vitro interaction between some of the plant extracts with drugs commonly 
used to treat malaria. 
6.2 Essential conclusions from the study 
Seasonal variation in yields and antiplasmodial activity 
The yields of the plant extracts varied between the wet and dry seasons. Plants collected in the 
wet season had higher yieldS than those collected during the dry season. The extracts from the 
plants S. disci/olius. S. stuhlmannii. 1. emarginella. and A. africana had significant 
antiplasmodial activity; i.e. below the arbitrarily set 50% inhibitory concentration (ICso ) of 25 
/-lglml. Ethyl acetate and methanol extracts generally had better antiplasmodial activity than the 
rest of the extracts, indicating that the principles responsible for antiplasmodial activity were 
polar compounds. The ethyl acetate extract of A. africana had the highest antiplasmodial 
activity. The extracts of S. disci/olius and I. emarginella. collected during the dry season, had 
significantly better activity than those collected during the wet season. 
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Is there cross- resistance between plant extracts and chloroquine? 
There was no significant difference between the antiplasmodial activity of the plant extracts 
against the chlororoquine- and sulphonamide-resistant K 1 and the chloroquine-sensitive D 10 
strain of P. Jalciparum. There was, in fact, a positive correlation between the activity of the plant 
extracts against both strains of P. Jalciparum (Pearson's coefficient; r = 0.9691, p=0.05). This 
suggests that malaria remedies derived from these plants could be effective against malaria 
caused by both chloroquine-sensitive and -resistant parasites. 
Ugandan traditional medicinal plants as sources of antimalarial lead compounds 
The isolates ACWI and AA2 from A. aJricana had in vitro antiplasmodial activity with ICso of 
l.51 (l.21-l.81) j.lg/ml and l.50 (l.33-l.67) j.lg/ml against the DI0 strain respectively. These 
isolates have even better activity against the chloroquine- and sulfonamide-resistant Kl strain. 
With this level of antiplasmodial activity, structural modifications can produce compounds with 
higher activity. The yields of these isolates was 0.00036% and 0.00049%, very low compared to 
the yield of artemisinin from Chinese Artimisia annua L by hexane extraction of 0.4-0.6% 
(Jansen, 2002). It is necessary to determine the conditions of growth, harvest and extraction of A. 
africana that would result in better yields to enable further studies of its isolates. The final 
structural elucidation of the isolates would also determine the possibility of producing synthetic 
analogues for further studies. 
In vitro interactions between isolates from plants with existing drugs 
The isolate ACWI from A. africana antagonised the antiplasmodial activity of artemisinin 
against both the K 1 and D 1 0 strains of P. falciparum, and chloroquine against the D 10 strain. An 
additive effect was observed between the isolate and chloroquine against the Kl strain of P. 
falciparum. These findings predict potential antagonism betw.een A. africana and the two drugs 
in vivo, and suggest that concurrent use of traditional medicines based on A. africana with either 
chloroquine or artemisinin could result in treatment failure. This study adds concurrent use of 
unstudied traditional medicines with antimalarial drugs to the list of factors affecting malaria 
treatment outcome. There is a need for more studies focusing on this concept, especially field 
studies, to determine its incidence and extent. 
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Effect of plant extracts on uptake of 3H-dihydroartemisinin (J H-DHA) 
This study demonstrated that P. jalciparum-infected erythrocytes accumulate 3H-DHA more than 
uninfected erythrocytes. The uptake of 3H-DHA by infected erythrocytes was characterised to be 
dose, temperature dependent, and saturable, suggesting involvement of a carrier protein. On the 
other hand, uninfected erythrocytes take up a small percentage of 3H-DHA erratically, but 
generally more at 37°C than at 4°C. The KI isolate of P. jalciparum was shown to have a more 
efficient mechanism of accumulating 3H-DHA than the D 1 0 strain of P. jalciparum. The isolate 
of A. africana, ACWl, inhibited the accumulation of3H-DHA by the Kl strain and enhanced the 
.. accumulation by the D 10 strain of P. jalciparum. Combination studies have shown an 
antagonistic relationship between the isolate and artemisinin with both strains of P. jalciparum. 
These findings suggest that two strains, K 1 and D 1 0, handle 3H-DHA differently and that the 
antagonism observed in vitro could be due to two mechanisms: inhibition of 3H-DHA 
accumulation and neutralising intracellular 'second messengers' of the artemisinin derivatives 
(the singlet oxygen radicals). 
The in vivo antimalarial activity 
The C57BL mice infected with the P. herghei (Anka) strain of rodent plasmodium produced a 
cerebral malaria disease model akin to the human disease. The difference observed was a high 
proportion of leukocyte monocytes. The mice did not tolerate the water extract of C. 
halicacahum in the study dose. The water extract of M joetida was well tolerated and protected 
the C57BL mice against cerebral malaria. This extract did not show significant in vitro 
antiplasmodial activity. The antimalarial activity observed in vivo could therefore be a result of 
active secondary metabolites in situ, or immune modulation. Although the mice were protected 
at different doses, they later developed malaria and died within 3 weeks. This extract has the 
potential of being developed into a herbal remedy that is useful in malaria treatment. 
The safety of the plant extracts 
The water extract of M joetida was well tolerated in mice at doses as high as 1000 mg/kg/day. 
The death of animals that received 500mg/kg/day of the water extract of C. halicacahum 
indicated a serious adverse event. Though no autopsy was done on the dead animals, the death 
with in 6 hours of extract administration suggests anaphylaxis as possible cause of death. This 
finding suggests that the water extract of M joetida is safe while that of C. halicacahum could be 
toxic. 
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6.3 The relevance of the study findings 
Traditional healers reported that collecting plant material during the dry season was desirable 
because of the advantage of drying from sun exposure. This study however revealed that yields 
and antiplasmodial activity of the study plants vary with season. Extracts from two of the study 
plants had better antiplasmodial activity during the dry season. The studies of Howe et al., 2002 
and Hoerkstra et al., 2001, suggest that there are metabolic changes in plants during conditions 
of stress, as in the dry season. These changes generally result into changes in chemical 
composition of plants. The variations in chemical composition with season have never been 
investigated for any of the plants involved in this study. The study on yields of artemisinin in 
Artimisia Annua L. confirms the existence of extensive variations in chemical composition of 
plants with season (Wallaart et al., 2000). 
To develop traditional medicines with antimalarial properties as sources of lead antimalarial 
compounds or herbal remedies for malaria, it is necessary to carry out studies to optimise 
conditions of growth, harvest and preparation so as to make the venture economically viable. 
The use of traditional medicines in self-medication is quite extensive and education of 
communities on the conditions of harvest that provide better yields and activity, would go a long 
way in improving malaria treatment outcome. 
Chloroquine-resistance is one of the greatest challenges facing malaria control programmes. 
New malaria remedies should generally not possess cross-resistance with chloroquine. The 
absence of cross-resistance between plant extracts and chloroquine increases the potential of 
Ugandan traditional medicines as a source of new antimalarial remedies. In fact the chloroquine-
and sulfonamide-resistant K 1 strain of P. Jalciparum was more wlnerable to one of the isolates 
from A. aJricana ACWI than the chloroquine-sensitive DIO strain. This situation can however 
be sustained only if traditional medicines continue to be used in the traditional way, and 
modifications in preparation and administration are accompanied by guidelines for rational use. 
The isolates AA2 and ACWI could act as lead compounds to new antimalarial drugs that require 
structural modifications to improve their antiplasmodial activity. Characterisation of these 
compounds showed they were sesquiterpenes (existence of a peroxide bond was not elucidated). 
Artemisinin, a plant derived compound, whose derivatives are now leading antimalarial drugs, 
. belongs to the same class of compounds (Hien and White, 1993). It is also interesting to note that 
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the plant A. afllwa L, from which artemisinin was isolated, belongs to the Asteraceae family as 
does A. africana.· Sesquiterpene peroxides with antiplasmodial activity have also been isolated 
from Senecio selloi and Eupatorium rufescens, both plants of the Asteraceae family (Ruecker et 
aL, 1996). This makes the plant family of Asteraceae a potential source of antimalarial 
sesquiterpene peroxide compounds. 
The existence of synergy among constituents of the methanol extract of I. emarginella and the 
ethyl acetate extract of S. discifolius is easy to imagine based on the ethnopractice of using plant 
combinations as reported in neighbouring Tanzania (Gessler et al., 1995). The findings of this 
study indicate that some plant principles act in synergy to produce the antimalarial activity. One 
could conclude that these traditional medicinal plants can be used only in crude form as anti-
malarial herbal remedies. 
There are no prior reports of interactions between chloroquine or artemisinin, and traditional 
medicines. There are however examples of interactions between herbal extracts and some of the 
drugs as discussed in the first chapter of this report (Roby et al., 2000, Mai et aL, 2000). While 
interactions observed in this study could be classified as adverse events, they do not undermine 
the potential of traditional medicines. Like other remedies, they call for extra caution and 
establishment of proper guidelines. The level of antimalarial activity shown by the plant M. 
foetida reveals a high antimalarial potential for this plant. This finding has not been reported 
before and calls for clinical studies to determine its effectiveness in the treatment of human 
malaria. 
6.4 Extent to which objectives have been met 
This study provided evidence of antimalarial efficacy in all the plants studied with the exception 
of C. halicacabum, suggesting a high antimalarial potential that Ugandan traditional medicinal 
plants have. The study also demonstrated that there is no cross-resistance between plant extracts 
with chloroquine. It also reveals extensive variations in extract yields, which is associated with 
time of collection. There is the need for optimisation of conditions of growth, harvest and 
preparation so as to make the production of malaria remedies from these plants commercially 
viable. The isolation of AA2, ACWI and ACW2 compounds with significant in vitro 
antiplasmodial activity, indicate that A. africana can be a source of lead antimalarial compounds. 
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6.5 Limitations and problems encountered during the study 
While the plant material used in this study was collected in the same way as traditional healers 
do, the methods of extraction were different in order to make the handling of extracts easier, as 
explained in the methodology. The selection and collection of plant material were done 
following the methods used by traditional healers, but the methods of extraction were different. 
The study also utilised in vitro systems and a murine model of cerebral malaria to determine the 
efficacy and safety of the study plants. These systems, however, differ from the situation 
observed in humans. The key components- absorption, metabolism and cellular binding- are 
lacking in in vitro systems. These must be taken into consideration in any attempt to extrapolate 
the results to humans. 
While the use of a murine malaria model increases the predictive value of our results, rodents do 
not handle drugs in exactly the same way as humans and, moreover, non-human species of 
Plasmodium are used (Anonymous, 1984). The disease model used in this study also lacks the 
insect vector, implying that it is not exactly representative of the pathogenesis of human malaria. 
Nevertheless, this model has been extensively used in the evaluation of antimalaria compounds 
and provides results that can be relied on in preliminary studies (WHO, 1973; Peters, 1975). 
6.6 Research prospects 
The findings of this study raise the need for conservation of the plant species that have been 
found to possess antimalarial potential. For all the plants with antimalarial potential, studies on 
the distribution of active principles with in different parts of the plant are necessary to ensure 
better harvesting. It is necessary to carry out agro-research aimed at improving the conditions of 
growth and harvest of these plants to achieve commercially viable yields. Furthermore, there is 
need to carry out clinical studies on plants like M joetida, to determine their efficacy and safety 
in human use. Plants with in vitro antiplasmodial activity need to be investigated for in vivo 
antimalarial activity and safety before these studies are done. 
There is need to carry out complete structural elucidation not only on the compounds isolated in 
this study but on several other isolates so as to establish their biosynthetic pathways and 
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structure-activity relationship. These could be used in any efforts to synthesize these compounds. 
With this information structural modifications can be done with the aim of improving their 
antimalarial activity. Information on plant biosynthetic pathways is necessary for any efforts 
towards the production of some ofthe antimalarial compounds in cell or tissue culture systems. 
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